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Prostate Cancer Screening: Outcomes and Risk Prediction 
Maria Frånlund, MD 
Department of Urology, Institute of Clinical Sciences 
Sahlgrenska Academy at University of Gothenburg, Sweden 
ABSTRACT 
The Göteborg Randomized Population-Based Prostate Cancer (PC) screening trial 
was started in 1995 to evaluate prostate-specific antigen (PSA) screening and its 
long-term impact on PC-specific mortality and PC incidence. The four papers 
included in this thesis present the outcomes of PSA-based screening and also 
describe aspects of the risk of PC at initial screening, during the 22-year follow-up of 
the programme, and after termination of screening. 
In this trial, 10,000 men born 1930–1944 were randomized and thereafter invited to 
PSA screening every second year from 1995 to 2014. An additional 10,000 men were 
randomized to the control group (i.e., not invited). The complete incidence of PC was 
ascertained by linkage to the Swedish Cancer Register and the Swedish Population 
Register. All relevant medical documentation was retrieved continuously for every 
man with PC. In our first study (Paper I), we investigated whether men with an 
elevated PSA level (³ 3 ng/mL) and voiding symptoms were at higher risk of PC; the 
results showed no association between such symptoms and an increased risk of PC. 
Thereafter (Paper II), we evaluated the long-term outcome in men with an initial 
PSA of < 3 ng/mL. We concluded that men died from PC despite “normal” baseline 
PSA and regular participation in the programme. Baseline PSA was strongly 
associated with long-term PC risk. Free-to-total PSA had no additive value to PSA in 
this PSA range. 
In our third study (Paper III), we assessed PC mortality and incidence in the 
screening and the control group after 22 years of follow-up, which showed that 
screening reduced PC-specific mortality by 29%. The absolute risk reduction has 
increased over the years, and the number needed to diagnose is now 9, which is an 
all-time low (NND=9). High risk of PC death was found in men who did not attend 
to the programme, men who started testing after the age of 60, and men who had a 
long life expectancy and terminated screening too early. Paper IV describes our 
evaluation of outcomes in men who stopped PSA screening after the age of 67–70. 
We found that participants with a PSA > 1.5 ng/mL (at their final screen) had a non-
negligible risk of a future Gleason score of ≥ 7 cancer, and later PC death. Notably, 
approximately 80% of these cases could have been detected and additional PC deaths 
prevented, if less than half of all men in the cohort had been offered additional 
testing (or other diagnostics).  
Keywords: prostate cancer, screening, prostate-specific antigen, mortality, prediction 
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1 INTRODUCTION 
Testing for a disease in people who have no symptoms is called screening. 
This strategy can help physicians find and treat cancer at an early stage, 
before symptoms occur and while it is still possible to “remove” or medically 
treat the disease. By the time symptoms appear, malignant cells may have 
begun to spread and treatment may no longer be curative. However, if a 
tumour is detected at an early stage, the risk of death from that specific 
cancer can be reduced. Still, it is important to keep in mind that even if 
screening can be associated with many benefits for some individuals, it might 
cause harms in others.  
Prostate cancer (PC) is a common disease that has a large impact on men, as 
well as on health-care providers, worldwide. The use of prostate-specific 
antigen (PSA) for screening is highly controversial, and organized PSA 
screening is not yet conducted in Sweden. Some of the difficulties lie in 
being able to test men who will benefit from PSA screening, and not those 
who may suffer from unwanted side effects secondary to diagnostics and 
overtreatment. A large proportion of men who are diagnosed with a screen-
detected PC have no advantage of early detection, because many PCs are 
slow growing, and other morbidities are more likely to contribute to the cause 
of death. 
The papers included in this thesis are all based on the Göteborg Randomized 
Population-Based Screening Trial, which was initiated in 1995. The 10th and 
final screening round was completed in 2014. This trial is unique in many 
ways, and it has the longest follow-up of all screening studies to date (22 
years). Mortality data from this period are presented for the first time in 
Paper III. At the start of the trial in the mid 1990s, PSA testing was not 
common in Sweden. Accordingly, the studied population was previously 
unscreened, an aspect that is impossible to replicate today. Indeed, it is 
difficult to outline and investigate what is currently called “opportunistic” 
and widespread use of PSA (men who are PSA testing outside the 
programme). Another strength with the Göteborg screening trial is that 
adherence was as high as 77%. 
The studies described in the papers included in this thesis focused on 
outcomes and risk assessment with the intention of improving our 
understanding of PSA screening and risk prediction in a screening setting. 
We regard PC screening as a challenging puzzle that needs to be solved! 
  Maria Frånlund 
 6 
1.1 THE PROSTATE 
Symptoms from the prostate and the lower urinary tract have plagued men 
since the beginning of time. The origin of the word “prostate” can be traced 
back to ancient Greece, and literally means “one who stands before” or 
“protector” (1). This is a rather suitable name, considering that the gland has 
the location of a gatekeeper to the male reproductive tract. Some of the 
secretions from the prostate can help protect both the urinary and the 
reproductive tract from harmful bacteria that enter the urethra and can 
potentially damage the sperm. 
The prostate gland is located below the urinary bladder and in front of 
(anterior to) the rectum, and it encircles the urethra. The apex of the prostate 
lies at the bottom of the pelvic floor, which is where the urethra enters the 
penile structures. The sphincters responsible for urinary control are closely 
connected to the prostatic part of the urethra, which is about 3 cm long. The 
seminal vesicles are located at the base of the prostate, close to the bladder 
and the ejaculatory duct, the latter of which transports the sperm from the 
testicles to the lumen of the prostatic urethra. The nerves mediating erection 
runs in the neurovascular bundles that are situated posterolaterally and 
symmetrically to the prostate in the space defined by the levator fascia, 
prostatic fascia, and Denonvilliers’ fascia. These nerves are sensitive and can 
be damaged during prostate surgery (2). 
Figure 1. The prostate is surrounded by vulnerable structures: the bladder, the rectum, nerves 
for erection, and major arteries and veins. (iStock.com/kocakayaali) 
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The prostate is an exocrine gland that, together with the seminal vesicles, it 
produces proteins and enzymes that regulate the viscosity of the semen. 
Starting at puberty, the gland grows to a volume of approximately 20 cm3 (at 
about age twenty). The prostate consists of glandular and fibromuscular 
tissue and secretes a clear, alkaline fluid that constitutes about one third of 
the semen ejaculate. The composition of the secretion supports sperm 
survival and motility outside the male body, and the fluid contains several 
constituents, such as citric acid, phosphatase, potassium, calcium, and zinc 
(3). The prostate gland is not a vital organ, indispensable for life or even for 
sexual function. However, after surgical removal of the prostate gland and 
seminal vesicles (prostatectomy), ejaculation is no longer possible.  
The prostate gland is an androgen-dependent organ and hormones are 
required for its normal growth and function. This was first recognised in 
1786, by dr Hunter who found that removing the testicles from young male 
animals prevented growth of the prostate.  
In the prostate, testosterone is converted to dihydrotestosterone (DHT), by 
the enzyme 5alpha-reductase. Androgen action is mediated by the androgen 
receptor (AR), which mediates the cellular response – and testosterone and 
DHT activity – by promoting transcription of certain genes. The primary 
treatment for metastatic PC is androgen deprivation therapy.  
1.1.1 Benign prostatic hyperplasia 
Enlargement of the prostate gland is a very common condition in ageing men. 
Furthermore, if they live long enough, most men will develop benign 
prostatic hyperplasia (BPH), which has been found at autopsy in 
approximately 40% of men in their 50s and in 70% in their 60s (4). The 
prostate of an average 25-year-old male weighs about 15–20 g (5), and the 
change in weight and size of the gland over time is subject to a considerable 
variation. Most men already display the histopathological characteristics that 
define BPH by the time they reach the age of 30. 
The hyperplasia in BPH is due to an increase in the number of stromal and 
epithelial cells in the prostate, which results in the formation of large nodules 
in the transition zone of the gland. Progressive enlargement of the prostate 
can lead to compression of the urethra and subsequent bladder outlet 
obstruction. It is also well known that PSA level and prostate volume are 
predictors of later BPH surgery (6). 
 
  Maria Frånlund 
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1.1.2 Voiding symptoms 
Symptoms from the urinary tract have often been called “prostatism”, 
although this term is no longer used (7). Today, we usually refer to voiding 
(obstructive) symptoms or storage (irritative) symptoms, and a patient can 
have mainly the former or the latter, or a combination of both. This can make 
treatment challenging. Voiding symptoms in men often indicate that BPH is 
the underlying cause (8). The obstructive symptoms of prostate enlargement 
can be secondary to an increased resistance in urinary flow, which can cause 
compensatory changes in the detrusor and bladder function. The initial signs 
of difficulties in emptying the bladder include hesitancy and straining, weak 
stream and intermittency. It is possible that impaired bladder contractility can 
successively lead to symptoms known as overactive bladder. However, 
symptoms such as urgency, increased frequency of micturition, reduced 
bladder-filling sensation, post-micturition dribble, urinary retention, and 
incontinence can be related to a variety of causes, for example urinary tract 
infections, strictures, neurological disease, or even bladder cancer (9). 
Voiding symptoms are common in the ageing population. A study 
comprising all municipalities in Sweden and based on postal questionnaires 
indicated that one third of men aged > 50 years suffer from urinary symptoms 
(10). This finding agrees with additional investigations conducted in Sweden 
(11, 12) and in other European countries (8). 
Figure 2. The relationship between prostatic 
enlargement, the symptomatology, and the 
presence of urodynamic obstruction, here 
illustrated by Tage Hald’s classical rings from 
1989 (13), showing the complexity of 
interaction. The three components are not 
always presented together. 
In most cases, symptoms from the prostate 
and/or bladder do not imply serious 
disease. However, clinicians in different 
disciplines often encounter patients who 
are anxious and experiencing discomfort and shame due to their voiding 
problem men also have an underlying fear of PC (14) and request urological 
examination and a PSA test (15), to ensure that there are no signs of cancer in 
the urinary tract. A worried wife or partner can also have a major impact in 
this context (16). Furthermore, the ongoing debate in the media regarding 
PSA testing has received much attention during the last decade and might 
have an impact on men’s urological awareness. 
Prostate Cancer Screening: Outcomes and Risk Prediction   
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1.2 UROLOGICAL EVALUATION OF THE 
PROSTATE AND URINARY TRACT 
Obtaining a medical history is the first step in assessing all patients, and it 
should include these aspects: duration and nature of symptoms, previous 
surgery, medication, and general health status. In some cases, urinalysis and 
culture can aid in diagnosis of an ongoing infection or inflammation in the 
urinary tract. In men with a confirmed infection, it is recommended to refrain 
from PSA testing until at least six weeks after successful antibiotic treatment 
(17). 
Several different methods are used to examine the prostate gland. One of 
these is digital rectal examination (DRE), which is performed to evaluate 
the size, consistency, and shape of the prostate. Indurations and nodules can 
be signs of PC and often develop in the peripheral zone (18). However, the 
effectiveness of DRE can be questioned, because many cancers are often too 
small to be detected by the physician’s finger, and one third of PCs are 
located anteriorly (18). 
Transrectal ultrasound (TRUS) is the imaging modality used most often for 
prostate evaluation (19). It is easy to access the prostate through the rectum, 
where the probe is introduced. Using TRUS, the urologist can measure the 
volume of the prostate and, to some extent, also visualize the different zones 
of the gland. However, there is a significant intra- and inter-observer 
variation (mean 5–10%) when assessing the size of the gland (20). As 
previously mentioned, even if a measurement of the prostate volume is 
correct, it is not necessarily correlated with the degree of the symptoms (21). 
A definite diagnosis (PC or BPH) can be made only after histological 
examination of the prostate tissue.  
Prostate biopsies are preferably taken under local anaesthesia and by needle 
aspiration. Ultrasound provides poor visualization of an actual tumour, and 
the TRUS-guided biopsies are focused mainly on the peripheral zone of the 
prostate. Thus, this approach can miss significant tumours and instead detect 
small, insignificant lesions. Additional tissue cores can be taken from other 
areas of the gland, and it can also be worth considering use of anterior 
sampling if the initial biopsies show benign findings with rising PSA. This 
invasive procedure can be associated with haematospermia (10–50%) and 
haematuria (10–80%) (22), as well as infectious complications. 
Approximately 3% of men who have biopsies develop a febrile urinary tract 
infection (23), and the re-admission rate has been calculated to 1–3%, 
depending on the healthcare system.  
  Maria Frånlund 
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Figure 3. The current TRUS guided 
technique, can miss significant tumours 
and “accidentally” detect small 
indolent cancers.  
 
Multiparametric magnetic resonance imaging (mpMRI) is a new diagnostic 
tool for evaluating the prostate gland. Studies of the use of MRI for detecting 
PC have indicated that MRI-based prostate-volume-adjusted PSA can 
improve the effectiveness of PSA for the diagnosis of men with high-
Gleason-sum PC (24). MRI is superior to TRUS due to its soft tissue contrast 
resolution, and it has also been suggested to be useful in the management of 
patients with BPH (25). In the recently published PRECISION trial (26), the 
use of risk assessment with MRI before biopsy and MRI-targeted biopsies 
were considered to be superior to TRUS-guided biopsies in men with a 
clinical suspicion of PC. With this approach, fewer men had to undergo 
biopsy, and more clinically significant cancers were identified. In Sweden, 
MRI is often used for early detection of PC and to select patients for active 
surveillance, and it has been recommended in the Swedish National 
Guidelines since 2017 (as part of the work-up process) (27). MRI-guided 
targeted biopsies improve diagnosis of PC (28), and a large study has been 
initiated in Göteborg (G2 study) to further asses the use of this modality in a 
screening setting. 
 
Figure 4. Template for biopsy 
location (targeted biopsy) after 
positive findings on MRI (adapted 
from; Nationellt vårdprogram 
2017-02-28, Version 1.2 (27). 
Reprinted with permission. This 
template is presently used by 
urologists, pathologists and 
radiologists in Sweden.  
 
A: base, B: central, C: apex,  
v: ventral, d: dorsal. 
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1.3 PROSTATE CANCER 
1.3.1 Epidemiology 
In Sweden, PC is the malignancy that is diagnosed most often, and it 
accounts for about one third of all cancers in men. Each year, approximately 
10,500 new cases are reported, and 2,400 men die from PC. As of January 
2018, it was estimated that the population of Sweden was 10 million, and that 
108,000 men were living with the disease (i.e. the prevalence).  
In a global perspective, there is considerable variation in the incidence and 
mortality rates for PC. In the mid 1990s, the availability of PSA testing 
started to increase, after which the reported incidence of PC increased in 
well-developed countries. This has also resulted in an apparent migration to 
earlier stages at diagnosis (29). PC is often described as a malignancy of 
elderly men, because it is rarely found before the age of 40, and most cases 
(> 75%) are detected in men aged ≥ 65 years (30). The average age at 
diagnosis in Sweden is about 70 years, and fewer than 150 men per year are 
diagnosed before the age of 50 (31). About one man in five is diagnosed with 
PC during his lifetime (32). The incidence increases with age, and thus it is 
assumed that, as the general life expectancy in men increases, there will be a 
concurrent rise in the incidence of PC. Nevertheless, there is a striking 
difference between the incidence and mortality curves for this disease, which 
implies that more men die with PC than from it. 
 
 
Figure 5. Age standardized  
PC incidence (blue) and 
mortality (yellow) in Sweden 
shown as number of PC cases 
and number of PC deaths per 
100,000. Adapted from 
www.socialstyrelsen.se and 
NORDCAN (mortality), 
www.ancr.nu.  
PC incidence in Sweden increased gradually over the years until it reached a 
major peak in 2005. In 2009, the first report from the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) showed that PSA screening 
had reduced PC mortality by ~20% (33). Short thereafter, another incidence 
peak occurred.  
  Maria Frånlund 
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The increase in incidence has been observed primarily in men aged ≤ 70 
years, which is also reflected in the increasing number of patients receiving 
curative treatment. Several factors contribute to the elevated incidence: an 
ageing population, increased awareness, better access to healthcare, and 
increased use of PSA testing. Today, many newly diagnosed PCs that are 
detected have low-risk features, and the tumour is still not palpable. Data 
from the Swedish National Prostate Cancer Register (NPCR) show that the 
proportion of such indolent cancers has increased from 14% in year 1998 to 
26% in 2016 (34). 
PC-specific mortality has also changed in Sweden, with the major decrease 
(approximately 40%) noted in men aged 60–79 years. Still, the pattern in men 
older than 80 is different in that it shows no such decline. According to the 
National Board of Health and Welfare, approximately 60% of men in Sweden 
who have died from PC have been older than 80 when they succumbed to the 
disease (data from 2017). 
 
Figure 6. PC mortality in various age groups, expressed as number per 100,000. Data from 
NORDCAN (32) www.ancr.nu.  
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1.3.2 Uncertainties in aetiology and diagnosis  
Slow-growing and harmless or fast-growing and aggressive 
All cancers are caused by damage to the DNA. Carcinogenesis is initiated 
when genetic changes trigger cells in the prostate to start growing out of 
control. This opposes the fact that cell proliferation, adhesion, and migration 
must be strictly regulated to ensure maintenance of the prostatic architecture. 
In most cases, the abnormal cells grow slowly and remain confined to the 
prostate, and therefore small and indolent cancers are unlikely to affect 
men’s health. The well-known autopsy study conducted by Sakr et al. (35) 
showed that insignificant low-grade PC is harboured by most men older than 
70 years and can already appear as early as age 30 in some men. The 
prevalence of these clinically latent tumours is estimated to be 20–50% in 
men aged > 50 years (36). Men with early low-grade PC usually have no 
symptoms from their cancer. However, these men can have voiding 
difficulties attributed to BPH, and both benign enlargement of the gland and 
PC can coexist.  
In other cases, PC presents with an aggressive behaviour, involving rapid 
tumour growth and death of the patient within a few years. Recent research 
has identified a genomic variant located in chromosome 19q13, that 
influences several genes that can potentially drive the PC to an incurable 
stage (37). Gao et al. (38) concluded that their findings based on 
manipulation of gene expression “reveal a plausible mechanism for 
aggressiveness of PC cells”. In men with PC, the genome exhibits various 
genetic mutations and chromosomal aberrations, and thus it is essentially 
certain that PC genetics will play an important role in risk prediction and 
targeted therapies in the future. 
Metastatic and advanced disease can cause severe morbidity such as localized 
bone pain, haematuria, and anaemia. Therefore, early detection is essential to 
increase the chance of treating high-risk PC within the “window of cure”. 
Since PSA testing was introduced in the mid 1990s, what is called a stage-
shift towards organ-confined and low-grade disease has been observed. This 
means that cancers are diagnosed at an earlier stage, which can help many 
men avoid spread of the disease. Helgstrand et al. (39) analysed data on 
19,487 men in Denmark who died from PC between 1995 and 2013 and 
found that most of those men had advanced or metastatic disease at the time 
of diagnosis. During the indicated time period, the proportion of men 
diagnosed with metastatic cancer decreased by 15.7%, and only 0.15% of all 
men had low-risk disease at diagnosis. All of the findings mentioned above 
are primarily the result of increased diagnostic activity, but unfortunately, 
  Maria Frånlund 
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this leads to overdiagnosis and subsequent overtreatment for men with an 
indolent PC. 
Another problem, discussed in a previous section, is that the diagnostic 
features of a biopsy-detected PC do not necessarily represent all lesions in the 
prostate, and the TRUS-guided random core technique might miss aggressive 
cancers in the anterior part of the gland. In other words, men diagnosed with 
low-grade PC might also harbour a high-grade PC. This makes risk 
prediction on an individual basis challenging. Hence, it is important to 
consider age and other comorbidities when estimating the life expectancy of 
men with localized disease (40). 
What causes prostate cancer? 
Risk prediction would be less complicated, if the aetiology of PC was better 
understood. Studies have indicated that environmental factors and genetics 
play a role in PC development and progression, although the only well-
established risk factors are old age, ethnicity, and family history. Cancer is 
caused by changes in the DNA in normal cells, and genetic alterations occur 
over time, thus older men are at greater risk. In other words, there are no 
known specific “triggers” for the disease. Inasmuch as this is a highly 
relevant topic, there are many innovative theories. 
Family history and genetics are associated mainly with aggressive PC (41), 
but only a small proportion (5–10%) of men have true hereditary PC, defined 
as more than three close relatives who are affected. It seems that men with 
hereditary PC have an earlier onset of the disease, but otherwise show the 
same clinical characteristics and survival as observed in men with sporadic 
PC (42). Genome-wide association studies have identified more than 100 risk 
loci (43), primarily in populations of European or Asian ancestry, although 
mortality rates are higher in populations of African descent (44). 
Inflammation and chronic infections can cause tissue damage and affect 
carcinogenesis in several organs of the body (i.e., stomach, penis, and 
cervix). It is possible that inflammatory changes and oxidative stress can 
cause cell alterations that promote neoplastic transformations. A study 
performed in Göteborg found proliferative inflammatory atrophy in tumours 
from PC patients treated with radical prostatectomy (45). It has been 
suggested that cytokines and inflammatory cells are associated with the 
progression of PC by facilitating angiogenesis and tumour growth (46).  
Also, recent studies have found a probable relationship between human 
papillomavirus (HPV-16) and an increased risk of PC (47). Furthermore, 
Prostate Cancer Screening: Outcomes and Risk Prediction   
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research has indicated that men with fewer sexual partners have a lower PC 
risk (48), which may be consistent with the HPV theory.  
Lifestyle in Western countries has been suggested to influence the risk of PC 
(49), and discussions have focused on smoking, nutritional factors, 
overweight, and even alcohol consumption Unfortunately, no effective 
preventative recommendations have been established. Zhao et al. (51) found 
a significant dose-response relationship between alcohol intake and risk of 
PC, starting with a low-volume consumption (> 1.3 up to < 24 g per day). 
Dairy products have also been discussed in relation to PC, and some data 
suggest that milk and other dairy products are associated with increased risk 
of PC and even disease recurrence (50, 51). It is not clear whether this effect 
is due to suppression of circulating vitamin D by calcium. It has also been 
proposed that fried foods might be related to PC risk (52). According to the 
Centres for Disease Control and Prevention, tobacco smoking is the most 
“preventable cause of deathˮ in the United States, whereas it appears that the 
association with PC is stronger for aggressive forms of the disease. 
Moreover, it seems that heavy smokers have a higher risk of PC-specific 
mortality (53). Physical activity is another factor that has been postulated to 
reduce PC risk (54) by four different mechanisms. (i) hormonal function 
(increased production of sex hormone-binding globulin, which results in low 
free testosterone levels); (ii) energy balance (storage of carcinogens can 
occur in visceral fat); (iii) immune function (effect on macrophages, 
lymphokine-activated killer cells, and cytokines); and (iv) antioxidant 
function (chronic exercise improves free radical defences by up-regulating 
activities of free scavenger enzymes and antioxidant levels). Physical activity 
may influence carcinogenesis (55) by suppressing dihydrotestosterone (DHT) 
activity (via inhibition of 5alpha-reductase). DHT is a promoter of BPH and 
prostate cells and possibly also a promoter of PC. Endurance athletes have 
been found to have lower basal levels of testosterone (56) known as the 
exercise-hypogonadal male condition. However, the epidemiologic evidence 
and the impact of these changes are still highly uncertain. 
Hormonal effects must also be considered, and many urologists are 
concerned that testosterone replacement therapy (TRT) may accelerate 
prostate growth, both BPH and PC. If lowering testosterone levels in men can 
make PC regress in men, does that mean that elevated levels of this hormone 
can cause PC to emerge? Although, testosterone is necessary for the 
development of PC, a meta-analysis carried out by Boyle and colleagues (57) 
found that “PC appears to be unrelated to endogenous testosterone levels, and 
TRT (for symptomatic hypogonadism) does not seem to increase PSA levels 
nor the risk of PC development”. Roddam et al. (58) performed a 
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collaborative analysis of 18 prospective studies evaluating sex hormones in 
serum and found no association between endogenous hormones and risk of 
PC. 
Can prostate cancer be prevented? 
Today, after years of different trials (59) no chemo-preventive method has 
been approved for systematic use, and many consider it rather unlikely that 
such approval will be granted. Earlier studies have provided results indicating 
that some micronutrients might protect against PC. However, the Selenium 
and vitamin E Cancer Prevention Trial (SELECT) (60) demonstrated that 
neither alpha-tocopherol nor selenomethionine offered any preventive 
benefit. On the contrary, the results of that trial indicated that men given only 
selenium, or vitamin E and selenium, were more likely to develop PC than 
men who were given placebo. 
Other investigations have assessed the effects of 5-alpha-reductase inhibitors, 
which have also been in the focus for chemoprevention. The REDUCE study, 
evaluated the effect of dutasteride treatment (61), and the phase 3, 
randomized, double-blind, placebo-controlled Prostate Cancer Prevention 
Trial (PCPT) considered whether treatment with finasteride could reduce the 
prevalence of PC during a 7-year period (62). The PCPT assessed 18,882 
men, aged ≥ 55 years, all of whom had a normal DRE and a PSA of  
< 3 ng/mL. DRE and PSA measurements were performed annually, and 
prostate biopsy was recommended for men with a PSA of ≥ 4 ng/mL. The 
PCPT was terminated 15 months earlier than planned. A 25% relative risk 
reduction in PC incidence was observed in the men treated with finasteride 
compared with those given placebo, although high-grade cancers (Gleason 
grades 7–10) were more common in the finasteride group. After 18 years of 
follow up, there was no difference in survival between the two study arms, 
and today this type of preventive strategy has essentially been abandoned. 
1.3.3 Diagnosis, staging, grading and risk groups 
Why are men diagnosed with prostate cancer? 
In Sweden, the majority of men diagnosed with PC have no symptoms, 
whereas others seek medical consultation for urinary problems. Since 1998, 
all cases of PC in Sweden are compiled by the National Prostate Cancer 
Register (NPCR) including the following: quality indicators and data on 
diagnostics, work-up, and treatment in all six healthcare regions in the 
country (63). Information from the NPCR is intended to provide quality 
assurance and can be used for comparison of regions and hospitals, aimed at 
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improving PC care in Sweden. The main reasons for the initiation of the 
medical investigation that led to PC diagnosis are listed in the annual report 
from NPCR (shown below). For approximately one third of the men 
diagnosed with PC in this country, urological work-up was initiated due to 
symptoms from the lower urinary tract (LUTS). 
 
Year 
 
Health 
Control 
 
LUTS 
 
Other 
symptoms 
 
Missing 
 
Total 
 
 
2004 2,800 (29) 3,473 (36) 3,107 (32) 401 (4) 9,781 
2005 2,744 (28) 4,124 (42) 2,381 (24) 508 (5) 9,757 
2006 2,611 (28) 3,967 (43) 2,121 (23) 486 (5) 9,185 
2007 2,912 (33) 3,684 (41) 1,913 (21) 406 (5) 8,915 
2008 3,078 (35) 3,658 (41) 1,793 (20) 335 (4) 8,864 
2009 4,465 (42) 3,821 (36) 1,917 (18) 325 (3) 10,528 
2010 4,125 (42) 3,472 (36) 1,914 (20) 255 (3) 9,766 
2011 4,196 (44) 3,311 (34) 1,872 (19) 229 (2) 9,608 
2012 4,178 (46) 2,871 (32) 1,699 (19) 266 (3) 9,014 
2013 4,738 (49) 2,891 (30) 1,747 (18) 226 (2) 9,602 
2014 5,613 (51) 3,127 (29) 1,621 (15) 571 (5) 10,932 
2015 5,410 (52) 3,120 (30) 1,669 (16) 252 (2) 10,451 
2016 5,623 (53) 2,995 (28) 1,748 (17) 224 (2) 10,590 
2017 5,572 (54) 2,654 (26) 1,788 (17) 223 (2) 10,237 
      
Table 1. Main reason for the initiating the medical investigations that led to the PC diagnoses 
shown by year of diagnosis (2004–2016). Adapted from (34) NPCR, with permission. 
Recent estimates from the NPCR indicate that 54% of all men with PC in 
Sweden were diagnosed after PSA testing performed as part of a general 
health control. These men had no particular symptoms, and national data 
show that more than half of all Swedish men aged 55–69 years have had a 
PSA test (64). This estimate can be compared to < 35% (before 2009).  
Today, in Sweden, clinical PC is not as common as during the pre-PSA era. 
Nevertheless, about 10% of newly diagnosed PC cases have metastatic 
disease at the time for detection, which can be compared with a rate of ~25%, 
20 years ago (34).  
The TNM staging system  
After confirmation of a PC diagnosis, additional examinations (i.e., 
computerized tomography, bone scintigraphy, and MRI) can be of value for 
further risk classification. A staging system based on the tumour-node-
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metastases (TNM) classification (65) is used to describe the extent of the 
disease (i.e., how far it has spread). The TNM system was recently updated 
(January 2018) (66), and it provides some key information: 
• T (tumour), gives the extent of the primary cancer 
• N (nodes), shows whether the disease has spread to lymph 
nodes 
• M (metastasized) indicates whether the cancer has spread to 
other parts of the body (i.e., bone or lung) 
Non-palpable cancers are designated (by the urologist) as clinical t-stage 1 
(cT1). Palpable tumours are classified as cT2, or as cT3 if they appear to 
penetrate the prostate capsule. Tumours that invade surrounding organs are 
called T4. Pathological staging is done by histological examination after 
surgical removal of the prostate (pT1–4). Regional lymph node metastases 
are classified in N stages: NX, N0 and N1: NX (not assessed), N0 (no lymph 
nodes present), and N1 (lymph nodes present).  
Surgeons have previously carried out explorative removal of obturator lymph 
nodes to evaluate metastasis and spread of disease before making a 
therapeutic decision. However, the role of imaging has grown in recent years, 
and mpMRI and computer tomography are now part of standard clinical 
management in many clinics, and mpMRI can aid detection and 
characterization of PC (67). M stages denote the following: MX, distant 
metastasis not assessed; M0, metastasis not present; M1, metastasis present. 
The stage of the disease is of prognostic value and can be useful when 
selecting treatment. Average survival is 2–4 years for M1 patients, whereas 
cancer-specific survival is 8 years for N1 patients (49).  
Choline or prostate-specific membrane antigen (PSMA) positron emission 
tomography (PET)-CT have shown to provide high specificity in the 
detection of lymph node metastasis prior to curative treatment, however low 
sensitivity has been reported (68, 69), and these modalities are still not 
recommended by the EAU guidelines.  
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T Primary Tumour 
  
TX Primary tumour cannot be assessed 
 
T0 No evidence of primary tumour 
 
T1 Clinically inapparent tumour that is not palpable 
 T1a Tumour incidental histological finding in 5% or less of tissue 
resected 
 T1b Tumour incidental histological finding in more than 5% of tissue 
resected 
 T1c Tumour identified by needle biopsy (e.g. because of elevated 
prostate-specific antigen [PSA level]) 
  
T2 Tumour that is palpable and confined within the prostate 
 T2a Tumour involves one half of one lobe or less 
 T2b Tumour involves more than half of one lobe, but not both lobes 
 T2c Tumour involves both lobes 
 
T3 Tumour extends through the prostatic capsule 
 T3a Extracapsular extension (unilateral or bilateral) including 
microscopic bladder neck involvement 
T3b Tumour invades seminal vesicle(s) 
 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles and/or pelvic wall 
 
N Regional Lymph Nodes 
 
NX Regional lymph nodes cannot be assessed 
 N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
M Distant Metastases 
 
 M0 No distant metastasis 
M1 Distant metastasis 
  M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
 
Table 2. TNM classification of prostate cancer. (Devised and adapted from the American Joint 
Committee on Cancer (70)). 
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Grading  
Grading of a tumour is performed by a pathologist who examines tissue 
samples from the prostate, and this entails both intra- and inter-observer 
variability (71). PC is graded using the Gleason grading system (72) 
developed by Donald F. Gleason (1920–2008). Tumour grade specifies the 
degree of tissue abnormality, and thus it indicates the aggressiveness of a 
tumour based on the histological pattern and microscopic appearance. PCs 
with a higher Gleason score (GS) are more aggressive and have a poorer 
prognosis. The sum of the most common patterns (grades) was initially used 
in such classification.  
In 2005, the International Society of Urological Pathology (ISUP) released an 
updated recommendation regarding the use of the GS grading system. The 
changes that were outlined led to an upgrading of PC diagnosed after 2005. 
The PC growth pattern is scored 1 to 5 (well to poorly differentiated), 
although grades 1 to 2 should rarely or never be used (73). In evaluation of 
biopsy materials, the most common grade and the highest (worst) grade 
diagnosed by the pathologist are summed to give a GS (ranging from 6 to 
10), and this is highly prognostic for patient outcome. In radical 
prostatectomy specimens, the GS comprises the two most common patterns, 
and it should also be recorded if some smaller foci with high grade cells are 
found (estimated per cent of the extent). Tissue samples from transurethral 
resections of the prostate (TURP) are graded in the same manner as samples 
from radical prostatectomy. 
 
 
 
 
 
 
Figure 7. The Gleason grading system, introduced by  
D. F. Gleason in 1966. (Adapted from (72)). 
It is preferable to use risk groups when evaluating PC treatment and 
prognosis (risk of the cancer being aggressive and lethal). The TNM 
classification system does not consider GS or PSA level for predicting 
prognosis. For example, a low-risk patient with T1c, GS 6, and a PSA of 9 
ng/mL will be quite similar to a patient with T2a, GS 6, and a PSA of 7 
ng/mL. By grouping patients with the same type, we can compare failure or 
success of any given treatment. 
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In Sweden, the definitions of groups are based on the well-known D’Ámico 
risk classification system (74). These are the main risk groups in the NPCR: 
• Very low-risk: T1c, PSA < 10 ng/mL, GS 6, PSA density  
< 0.15 ng/mL, ≤ 4 cores with PC (at least 8 taken), cancer 
length < 8 mm 
• Low-risk: T1–2, GS 6, and PSA < 10 ng/mL 
• Intermediate risk: T1–2, GS 7, and/or PSA 10–20 ng/mL 
• Localized high risk: T1–2, GS ≥ 8, and/or PSA 20–50 
ng/mL 
• Localized advanced: T3 and PSA < 50 ng/ml 
• Regional metastasized: T4 and/or N1 and/or PSA 50–100 
ng/mL, M0, or MX  
• Distant metastasized: M1, bone scan with signs of 
metastases, and/or PSA ≥ 100 ng/mL 
A similar risk stratification system is being used in the Göteborg randomized 
screening study (75): 
 PSA  Gleason score  T stage 
      
Low risk < 10 ng/mL  ≤ 6  T1 
Intermediate 10–19.9 ng/mL and/or ≤ 7 and/or T2 
High risk 20–99.9 ng/mL and/or ≥ 8 and/or T3–4 
Advanced ≥ 100 ng/mL    M1 and/or N1 
      
Table 3. Definition of risk groups in the Göteborg screening trial. 
To reduce overdiagnosis and overtreatment, various measures and 
nomograms have been suggested for pre-treatment evaluation of patients. The 
Epstein criteria were developed in 1994 and have become a widely used 
tool for risk prediction in men with localized disease (76). These criteria 
define insignificant PC as follows: T1c, PSA density < 0.15, GS 6 at biopsy, 
< 50% PC in a single core, and < 3 of the cores positive for PC. However, in 
a review published in 2011, the same authors concluded that “the Epstein 
criteria have suboptimal accuracy for predicting insignificant prostate cancer” 
(77).  
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1.3.4 Treatments for localized disease 
Early detection and treatment of PC is nothing new, considering that it was in 
1905, that Hugh Young suggested that a DRE could detect changes in the 
prostate that would lead to early diagnosis and interventions (78). Men who 
are diagnosed with localized disease have several options. Those who have a 
life expectancy of more than 10–15 years can be offered curative treatment 
that includes surgery, external beam radiotherapy, and also brachytherapy 
(both alone and in combination with external radiation). Less invasive 
alternatives are cryotherapy and high-intensity focused ultrasound (79), 
although the latter is not applied in Sweden (due to lack of evidence). 
Men with symptomatic and advanced PC or disseminated disease are offered 
hormonal and palliative treatments. Recently, novel antiandrogens 
(abiraterone and enzalutamide) were introduced for the treatment of 
metastatic castration-resistant PC. These drugs can increase survival in this 
group of patients, but they are very costly and less than one third of 
potentially eligible men in Sweden received such treatment in 2015–2016 
(80). Today, these drugs are introduced at earlier stages of PC.  
Expectant management 
Men with a low-risk PC should primarily be offered active surveillance 
(AS), which is a management strategy intended to help avoid unnecessary 
treatment and adverse effects. Men with signs of advancing disease (assessed 
as the proportion of positive biopsies/volume of cancer) can be offered 
curative treatment. It should be noted that AS is not equivalent to “watchful 
waiting”, a strategy that involves monitoring without curative intent, but 
rather it aims to manage symptoms in men with clinical progression. 
AS has been shown to reduce overtreatment in patients with low-risk PC 
without compromising cancer-specific survival at 10 years (81). However, 
inclusion criteria and programmes for AS vary with regard to both protocol 
and practice. The selection criteria for most programmes are based on 
D’Ámico classification of low-risk PC (≤ cT2a, PSA < 10 ng/mL, GS ≤ 6) 
(82). The Study of Active Monitoring in Sweden (83), which was initiated in 
2011, is a prospective multicentre investigation of AS for low-risk PC. The 
primary endpoint is conversion to active treatment, and secondary endpoints 
include symptoms, distant metastases, and mortality. Five hundred patients 
are to be included over a period of 5 years, and they will be followed for  
10–15 years. Hopefully the results will increase knowledge on this topic.  
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Also of interest, one of very few studies to report long-term outcomes after 
AS was conducted by Arnsrud Godtman and colleagues from the Göteborg 
screening trial (84). They have concluded that some men will miss their 
chance of cure while on AS, and that this type of monitoring is only suitable 
for patients with very low-risk features.  
Curative treatment 
A common treatment option in localized PC is radical prostatectomy (RP), 
which entails removal of the prostate gland and the surrounding tissue (to 
various degree). This can be done with a retropubic or perineal approach. 
Terence Millin performed the first retropubic RP in 1945. The technique was 
further developed in the 1980s, when Patrick Walsh explained the anatomical 
and pathological considerations related to preservation of sexual function (2). 
Nerve-sparing surgical removal is important to preserve as much function as 
possible. The conventional laparoscopic RP technique appeared in the 1990s, 
but it was never fully established due to a long learning curve and data 
showing no advantages compared with open surgery (85). The first robot-
assisted laparoscopic radical prostatectomy was performed in 2001, and since 
then this method has been widely established, despite the limited proof of 
better oncological and functional outcomes (86, 87). Nonetheless, men who 
undergo such robot-assisted surgery have shorter hospital stay and receive 
fewer blood transfusions (86). Approximately 400 operations are performed 
each year at Sahlgrenska University Hospital in Göteborg, and the surgical 
outcomes are freely available at www.npcr.se (RATTEN).  
 
Figure 8. The author in the operating room. Robot-assisted radical prostatectomy at the 
Sahlgrenska University Hospital. (Photo: Lennart Wiman, 2012) 
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The Swedish SPCG-4 trial randomly assigned approximately 700 men with 
localized PC to surveillance or radical prostatectomy, with a follow-up period 
of 23 years. Surgery was found to be beneficial and associated with reduction 
in all-cause mortality (56% vs. 69%), PC mortality (18% vs. 29%), and 
metastatic disease (26% vs. 38%) (88).  
Curative treatment also includes radio therapy (RT). In the 1960s, this was 
given as high-energy X-ray that included high doses in surrounding tissues, 
affecting the bladder and the rectum. Since then, this technique has been 
further developed, and even higher doses are used today, and the treatments 
can be delivered from an external beam source or as brachytherapy. With a 
dose-escalating regimen, 78 Gray (Gy) can be given. and more than 100 Gy 
can be used to treat localized disease by combining external therapy and 
brachytherapy. In 2009, the SPCG-7 study reported that, in patients with 
high-risk or locally advanced PC, adding local radiotherapy to endocrine 
treatment reduced the 10-year PC-specific mortality by ~50% (89). 
Side effects of treatments 
Early detection and treatment of PC saves lives, but the drawback is side 
effects in terms of erectile dysfunction and incontinence. The LAPPRO study 
(87) evaluated functional outcomes after both open and robotic surgery and 
showed that, at 12 months after surgery, approximately 20% of men were 
incontinent and as many as 70–75% had erectile dysfunction. Radiotherapy 
can induce proctitis with haemorrhage and irritative voiding symptoms. 
Carlsson et al. (90) investigated the excess burden of treatment side effects in 
screened men, and their data suggest that 120/10,000 more men will become 
impotent and 25/10,000 more will need incontinence pads postoperatively 
among men invited to PSA screening. Studies have attempted to estimate the 
extent of overtreatment resulting from PC screening, but the results vary 
because evaluated populations differed with regard to age and comorbidities, 
as well as the time periods under consideration (91). Further research is 
needed to learn how to differentiate between men with life-threatening 
cancers and those who can be safely kept under surveillance. In the quest for 
a more selective approach, nomograms and genetic tests are rapidly 
emerging. New biomarkers and imaging may also guide us in the future. 
However, we should always consider the well-known phrase from the 
Hippocratic oath: “primum non nocere”– first, do no harm.  
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1.4 BIOMARKERS 
The introduction of biomarkers for diagnosis and follow-up dramatically 
changed the practice of oncology. The term “biological marker” was 
introduced in the 1950s (92), and, in 1998, the US National Institutes of 
Health (NIH) defined a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (93). Cancer biomarkers can be produced by a tumour or by the 
human body in response to a malignant process. In 2011, Shariat et al. (94) 
described six uses for biomarkers in the management of PC:  
1. Detection/Screening: when evaluating patients/men with 
either symptoms of or risk factors for PC. 
2. Diagnostic: Establishing the absence/presence of cancer, when 
standard histopathology is insufficient. 
3. Prognostic: predicting the outcome in patients, in terms of their risk 
of recurrence, progression, or death, and thereby allowing for 
individualized management. 
4. Predictive: predicting and/or monitoring the effectiveness of a 
treatment, to aid selection of the best treatment modality for an 
individual patient. 
5. Therapeutic target: identifying the molecular target of a specific 
therapy and thereby establishing whether an individual patient will or 
will not respond; no such biomarker is currently in clinical use for 
any PC treatment. 
6. Surrogate endpoint: as a substitute for clinically relevant endpoints 
when assessing a particular treatment regarding its clinical benefits 
and harms (or lack thereof); replacing traditional endpoints (e.g., 
death, morbidity, and recurrence) with biomarker-based endpoints 
can reduce the time and costs of clinical trials. 
The use of biomarkers is a rapidly emerging field (e.g., including 
proteomic/genomic platforms, circulating tumour cells and urine-based 
analyses), and several promising biomarkers are currently being evaluated 
(95). There is a great potential in future profit for those who find a suitable 
biomarker considering that several of the new tests are associated with high 
costs. 
This chapter specifies and discusses some of the most well-known tests 
(mainly blood-based markers). PSA is used as a screening tool in the 
Göteborg randomized population-based screening trial. 
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Prostate-specific antigen  
Unlike many other malignancies, PC has a long history of biomarkers. As 
early as the 1930s, it was known that serum concentrations of prostatic acid 
phosphatase (PAP) are elevated in men with metastatic PC (96), and 
therefore PAP was used for many years as a clinical biomarker for disease 
progression. Research on PC biomarkers continued, and in the 1980s PAP 
was replaced by what is arguably still the most useful of all cancer 
biomarkers, namely, PSA. The introduction of PSA as a diagnostic test for 
PC completely changed the epidemiology and the clinical management of 
this disease. PSA testing has been widely used since the 1990s, not only for 
clinical detection and screening of PC, but also for monitoring men who have 
the disease and are under surveillance, before and after treatment. However, 
it is difficult to find a cut-off value with high specificity and adequate 
sensitivity (97).  
The early research on PSA was conducted in the 1960s and 1970s. At that 
time, antigens in semen that could be associated with infertility were assessed 
by several groups (98). One of these antigens was the protein PSA, an 
enzyme that was also evaluated as a forensic marker for rape victims (99). In 
healthy men, PSA is most abundant in seminal fluid, where the concentration 
is one million times higher than in serum (100). In 1979, PSA was purified 
from prostatic tissue (101), and in 1987 Stamey et al. (102) published data 
showing that PSA was more sensitive than PAP in detecting PC. Studies 
performed a few years later suggested that PSA could be useful in early 
detection of PC. Catalona et al. (103) conducted a clinical trial including 
6,630 men and found that detection of PC was improved by using a 
combination of PSA testing with a cut-off of 4 ng/mL and clinical 
examination (DRE). The United States Food and Drug Administration (FDA) 
approved PSA as a diagnostic marker for PC in 1994. Nevertheless, the 
specificity is poor when using cut-offs with sufficient sensitivity, and the 
optimal PSA threshold for proceeding to a prostate biopsy has been discussed 
intensely ever since the FDA authorization. 
PSA biochemistry and physiology 
PSA is a member of the kallikrein family of proteases and is also known as 
human kallikrein 3 (hk3). This androgen-regulated glycoprotein is secreted in 
high concentrations by the prostatic ductal and acinar epithelial cells. PSA is 
a serine protease with chymotrypsin-like activity. Its natural substrate 
consists of the proteins that make the seminal fluid gel-like, and it cleaves 
those proteins to liquefy the seminal fluid (104). Hence the physiological 
function of PSA is considered to be promoting sperm motility (105).  
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PSA is also produced by neoplastic cells originating from the prostate 
epithelium, although at somewhat lower levels and in varying amounts 
compared with benign epithelial cells (94, 106). The reason that both BPH 
and PC raise the serum PSA is that the architecture of the normal prostate 
membrane prevents PSA from reaching the circulation: only a very small 
proportion (one millionth) of the PSA leaks over into the bloodstream. Most 
prostatic diseases and traumata, including inflammation (prostatitis), BPH, 
cancer, and biopsy, disrupt the epithelial layer and the basement membrane 
(107). Although the serum PSA is usually raised in men with clinically 
relevant PC, some poorly differentiated PCs do not produce any PSA at all. 
Molecular subgroups of primary PC with characteristics similar to those of 
metastatic disease have been described (108). 
Free/Total PSA 
PSA occurs in serum in several molecular forms that can be either free 
(designated fPSA) or bound to protease inhibitors as stable covalent 
complexes. The bound forms are collectively known as complexed PSA 
(cPSA). Complexes with alpha-1-antichemotrypsin and α2-macroglobulin are 
predominant (109), and fPSA constitutes 5–30% of the PSA in serum. 
The ratio of free to total PSA (F/T PSA) is known to be lower in men with 
PC than in men with BPH, although the magnitude of this difference varies 
between studies (109, 110). Hence F/T PSA, which is often expressed as the 
percentage of free PSA (%fPSA), may help discriminate between men with 
BPH and men with PC. In 1998, Catalona et al. (111) detected PC on biopsy 
in 56% of subjects with F/T PSA < 10% but in only 8% of those with  
F/T PSA > 25%. In that study F/T PSA was validated in PSA ranges of  
4–10 ng/mL. The authors suggested that F/T PSA ≤ 25% could serve as the 
criterion for biopsy in the absence of a palpable nodule in the prostate. In 
Sweden, many centres routinely use F/T PSA for diagnostic decisions, and 
many laboratories automatically analyse F/T PSA as a reflex test if the PSA 
is within a certain range. A laboratory usually sets the cut-off at 18%, but as 
with PSA, no clear threshold can free the man from PC. 
The interest in different molecular forms of PSA as biomarkers has 
accelerated. Various combinations of kallikrein biomarkers are often 
regarded as the future of PC diagnostics, because they offer increased 
specificity compared with PSA only and thereby reduce the number of men 
who require a prostate biopsy (see section on the 4Kscore).  
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PSA density 
PSA alone is far from a perfect biomarker, but its diagnostic performance 
might be enhanced by analysing PSA kinetics (see below) and by relating the 
PSA value to the prostate volume (PSA density). Early reports concerning the 
usefulness of PSA density for selecting men for prostate biopsy have 
presented conflicting results (112, 113). Higher densities (> 0.10–0.15 
ng/mL/cm3) are more suggestive of PC, whereas lower densities are more 
suggestive of BPH. Nordström and colleagues (114) recently published an 
analysis of the utility of PSA density, which was conducted as a prospective 
study of 5,291 men with PSA ³ 3 ng/mL. This well-designed investigation 
suggested that omitting biopsy for men with a PSA density of £ 0.07 ng/mL3 
would save 20% of the men from having a biopsy, albeit at the cost of 
missing 7% of the cancers with GS 7–10. Thus, although PSA density might 
provide support for decisions regarding biopsy and spare some men from the 
morbidity associated with this invasive procedure, the clinical guidelines 
issued by the European Association of Urology (EAU) (115) and the 
American Urological Association (AUA) (116) do not advocate the use of 
PSA density for diagnostic decisions.  
PSA kinetics 
Rising PSA levels can reflect PC progression. Different ways of measuring 
the rate of increase in PSA are collectively called PSA kinetics, and the two 
applied most often are PSA velocity (PSAV) and PSA doubling time (PSA-
DT). Early research indicated a clear prognostic value of PSA kinetics. For 
example, the often cited study by D’Ámico et al. (117) showed a higher PC 
mortality after radical prostatectomy and after radiotherapy in men whose 
PSA had increased more than 2 ng/mL the year before diagnosis. However, 
later investigations (discussed below) have not obtained similar results 
regarding PSA kinetics as an adjunct in the diagnostic process. According to 
the EAU guidelines, PSA kinetics “may play a prognostic role in the 
treatment of PC, but they are of limited diagnostic value” (115).  
PSAV is a measure of the annual change in PSA, given in ng/mL/year (as 
discussed in Paper IV). PSAV has been reported to provide information to 
aid decisions concerning biopsy and the timing of the next PSA test. In 1992, 
Carter et al. (118) were the first to publish data on the rate of change in PSA 
values over time. PSAV can be calculated in several different ways, for 
example, by using the first and the last value only, and by performing 
regression analysis using all available PSA measurements over a certain 
period of time. Carter and co-workers (119) also specified that at least three 
consecutive measurements made over a 2-year period must be evaluated. 
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The Baltimore Longitudinal Study of Aging showed a strong association 
between cancer-specific survival and PSAV 10–15 years before diagnosis 
(120). Based on such findings, the AUA (116) and the National 
Comprehensive Cancer Network (NCCN) presented clinical 
recommendations that men with a PSAV of > 0.35 ng/mL per year should 
consider having a prostate biopsy, even if they have a normal DRE and PSA 
below the standard cut-off. However, the results of some later prospective 
studies indicated that PSAV offers no additional diagnostic value compared 
with PSA alone (121, 122). In the PCPT (123), PSAV lost its independent 
predictive value after adjustment for the absolute PSA value and standard 
clinical variables. 
In 2009, Vickers et al. (124) published a systematic review of 12 studies that 
compared PSAV with total PSA (tPSA) only for predicting PC on biopsy. 
These investigators found several methodological limitations of the 12 
studies and no strong evidence supporting the use of PSAV in clinical 
decision-making. In 2011, the same authors reported that taking biopsies in 
men with a low PSA level but a high PSAV led to a large number of 
unnecessary biopsies (125), and that there was limited evidence supporting 
the AUA and NCCN guidelines recommendations regarding the use of 
PSAV. Vickers and colleagues explained it as follows: “It is unclear why a 
marker that predicts aggressive PC many years in the future should be used to 
suggest immediate biopsy to patients”. The interest in PSAV declined after 
publication of these reports. Nevertheless, many urologists have a “clinical 
feeling” for the importance of changes in PSA levels and use an estimate of 
the PSAV in clinical practice. There is much “background noise” (e.g., 
transient rises in the PSA level caused by BPH and biopsies detecting 
indolent PC regardless of the PSAV) that probably had a negative effect on 
the ability of the mentioned studies to assess the association between PSAV 
and clinically significant PC.  
Data from a recent Danish study (126) of 7,455 men who had multiple PSA 
measurements suggested that the long-term PSA changes could help 
identifying men with low probability of PC mortality. In their investigation, 
503 men aged 30–80 years, with and without PC, who had repeated PSA tests 
over 20 years (and up to 28 years before diagnosis), were analyzed. The 
authors concluded that “long-term PSAV in addition to baseline PSA 
improved classification of risk of PC and mortality”. 
PSA doubling time (PSA-DT) is another method of measuring PSA kinetics 
(127). It measures the exponential increase in PSA over time.  
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Human glandular kallikrein 2 
All members of the human tissue kallikrein gene family code for proteases. 
There are at least 15 such genes, and they share important characteristics, 
including mapping at the same chromosomal locus (19q13.4) (128). Human 
glandular kallikrein 2 (hK2) has been described as a valuable predictive 
marker for the detection of PC, in some studies as even better than tPSA REF 
The hK2 protease shares 80% amino acid identity with PSA, and, similar to 
PSA, several forms of hK2 (i.e., free hK2 and hK2-ACT) can be detected in 
serum. Free hK2 is associated with higher GS (129). The levels of hK2 in the 
prostate, semen, and serum are less than 2% of the corresponding PSA levels. 
It has been suggested that hK2 can be useful in predicting the outcome in PC 
patients treated with radical prostatectomy (130), and several studies have 
concluded that this biomarker has an additive role in PC detection. 
Prostate Health Index  
The Prostate Health Index (PHI) is a mathematical formula that combines 
tPSA, fPSA, and [-2]proPSA to give a single score that can be used to aid 
decision-making for men with PSA values of 4–10 ng/mL (131, 132). A PHI 
value is calculated using the formula ([-2]proPSA/freePSA) x √PSA, based 
on the knowledge that men with higher tPSA and p2PSA and lower fPSA 
more often have clinically significant PC. In 2011, Catalona et al. (133) 
published results from a multicentre study of PHI for PC detection in 892 
men with moderately elevated PSA and benign DRE. These researchers 
found that the mean PHI scores were 34 and 49 for men with negative and 
positive biopsies, respectively. With a sensitivity of 80–95%, PHI had a 
greater specificity for discriminating PC than tPSA and F/T PSA. The area 
under the curve (AUC) was 0.70 for PHI compared with 0.53 for PSA and 
0.65 for F/T PSA. PHI has been approved by the US FDA and is marketed 
commercially by Beckman Coulter Incorporated. 
The four-kallikrein panel (4K score) adds clinical information 
In some ways it seems unlikely that a single biomarker will be “good 
enough” to make a definite and exact decision regarding diagnosis and/or 
prognosis of PC. To improve the accuracy, a research group led by Hans Lilja 
and Andrew Vickers developed a statistical model (the four-kallikrein [4K] 
panel) for predicting biopsy outcomes that is based on age, DRE, tPSA, 
fPSA, intact PSA, and hK2. In a study of 740 men participating in the 
Göteborg screening trial, these investigators used the 4K model to determine 
whether biopsy should be performed (134). The authors report that, “using a 
20% risk of PC as the threshold for biopsies, would have reduced the number 
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of biopsies by 57% and missed only 31 out of 152 low-grade and 3 out of 40 
high-grade PCs”. Adding the 4K panel increased the AUC for PC detection 
from 0.68 (with a base model with PSA and age) to 0.83. Similar 
observations were made in the French section of the ERSPC (135), which 
found that the corresponding AUCs were 0.63 and 0.78. Furthermore, it can 
be concluded that using the model in the Dutch section of the ERSPC would 
have saved 49% of the men from undergoing biopsy, at the cost of missing 
14% of the high-grade cancers (136). The 4K panel has also been tested in 
men who had previously undergone biopsy during screening (137). That 
analysis demonstrated that applying the 4K panel to 1,000 men with 
persistently elevated PSA after an initial negative biopsy would reduce the 
number of biopsies by 712 and miss or delay the diagnosis of 53 cancers.  
The 4K panel is marketed by OPKO Health Ltd. under the name 4Kscore®, 
and it is calibrated to identify high-grade PC on biopsy. An investigation 
applying the 4Kscore to participants in the Malmö Diet and Cancer Study 
was recently published (138). The results showed that 7.7% (one in 13) of 
5,263 men aged 60–73 years with a PSA of ≥ 2.0 ng/mL died from PC within 
15 years after the analysed blood sample was collected. By using the 4Kscore 
with a cut-off of 7.5% risk of high-grade cancer, the men could be split into 
two groups: a high-risk group with a 13% (one in eight) chance of dying from 
PC within 15 years, and a low-risk group with only a 1.7% (one in 59) 
chance. This showed that men in the high-risk group should have received 
further evaluation, such as an MRI or a prostate biopsy, whereas the men in 
the low-risk group could have safely avoided a biopsy. Also, monitoring the 
PSA in the men in the low-risk group might have further lowered their long-
term risk. The 4Kscore test is included in the 2017 NCCN and the 2016 EAU 
Prostate Cancer Guidelines (115). 
Both the PHI and the 4Kscore have been developed for predicting the 
outcomes of first-time biopsies. It has also been shown that these strategies 
perform better as diagnostic tests compared with PSA alone. Moreover, a 
study directly comparing the PHI and 4Kscore constituted similar 
performance of these two tests (139). However, it should be noted that the 
cited investigation did not include men with PSA < 3 ng/mL, and significant 
cancers can be found in as many as 25% of men with PSA in the range  
2–3 ng/mL (140). 
The STHLM3 model: adding clinical information and genetic markers 
The Stockholm3 (STHLM3) model is a new PC diagnostic test that combines 
the analysis of five serum biomarkers (tPSA, freePSA, hK2, MSMB and 
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MIC1) and 254 genetic markers (SNPs), risk factors (age, previous biopsies 
and family history), and clinical variables (DRE and prostate volume) (141). 
It seems that performance of this model is similar to that of the 4Kscore and 
the PHI tests, but to date only three studies of the STHLM3model have been 
reported, one of which assessed this model in combination with MRI (142). 
The STHLM3 test predicts the risk PC with a GS of ≥ 7 PC on biopsy. 
Single-nucleotide polymorphisms (SNPs) are single-nucleotide (A, T, C, or 
G) alterations in the genome. SNPs normally occur in the DNA, most often in 
the DNA between genes. Genome-wide association studies have identified at 
least 150 SNPs associated with the risk of PC (143), and approximately 30% 
of the familial risk is due to theses variant mutations.  
The first study of the STHLM3 model was published in 2015, and invited 
145,905 men for evaluation of PC risk (141). In a stepwise logistic regression 
analysis, the risk factors (i.e., age, family history, and biopsy history), the 
combined genetic score, all individual plasma protein biomarkers, and the 
clinical variables (i.e., prostate examination and prostate volume) all 
contributed significantly to the multivariable model. In a second analysis of 
the STHLM3 model, Ström et al. presented results obtained using an updated 
version of the model (144), in which intact PSA was removed and analysis of 
the G84E mutation in the HOXB13 gene was included (shown below). 
 
Table 4. Performance in predicting GS ≥ 7 disease for different variables included in the 
STHLM3 model. MSMB denotes microseminoprotein-beta, MIC1 macrophage inhibitor 
cytokine-1 and HOXB13 homeobox B13 gene. 
Risk factors  
AUC (bivariate) 
95% CI  
AUC (cumulative) 
95% CI 
 
Age 0.59 (0.57–0.61) 0.59 (0.57–0.61) 
Digital rectal examination 0.63 (0.61–0.64) 0.63 (0.61–0.65) 
Previous biopsies 0.61 (0.59–0.63) 0.65 (0.63–0.66) 
Prostate volume 0.67 (0.66–0.69) 0.71 (0.69–0.73) 
Family history 0.59 (0.57–0.61) 0.71 (0.70–0.73) 
Free PSA 0.65 (0.63–0.67) 0.72 (0.71–0.74) 
Free/total PSA 0.65 (0.63–0.67) 0.73 (0.71–0.74) 
Intact PSA 0.58 (0.56–0.60) 0.74 (0.72–0.75) 
hK2 0.59 (0.57–0.61) 0.75 (0.74–0.77) 
MIC1 0.59 (0.57–0.61) 0.75 (0.74–0.77) 
MSMB 0.60 (0.58–0.62) 0.76 (0.74–0.77) 
HOXB13 0.59 (0.56–0.60) 0.76 (0.74–0.77) 
Genetic score 0.61 (0.59–0.63) 0.76 (0.74–0.77) 
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The new model was fitted to data from the STHLM3 training cohort, and the 
authors reported that this adjustment “slightly improved the AUC” compared 
with previous results (0.75 vs. 0.74). The AUC for PSA alone was 0.58 (95% 
CI 0.57–0.60). However, genetic testing requires well-informed men, and 
there are several ethical considerations with this method (145). Furthermore, 
the additive value of the genetic score in the STHLM3 model has been 
questioned (146) and freePSA, intact PSA and hK2 are also incorporated in 
the model constituting the 4Kscore® (mentioned above).  
A urine test for prostate cancer antigen 3 (PCA3)  
The PCA3 gene is expressed only in the prostate, and in 1999, scientists 
reported that this gene was highly overexpressed in PC compared with 
normal and BPH tissue (147). A diagnostic method using polymerase chain 
reaction (PCR) is applied to detect PCA3 mRNA in urine, and this test has 
been evaluated in several clinical investigations. In 2012, the US FDA 
approved the PCA3 assay, which is called PRoGensa®, and studies have 
provided evidence that it might be useful in reducing the number of negative 
biopsies (148, 149). The PRoGensa assay is indicated for use in combination 
with other clinical data in men aged ≥ 50 years who have had previous 
negative biopsies. Prior to urine collection, a DRE should be performed, and 
pressure should be applied on the prostate. Although the brochure given to 
physicians does explain that such pressure should not entail a “prostatic 
massage”, it is highly possible that the procedure will result in some 
discomfort for both the patient and the doctor. 
The ERSPC risk calculator (RC1–6) 
Over the last 10 years, there has been extensive development of nomograms 
and risk calculators for the prediction of PC-positive biopsy. Prediction tools 
are intended to support physicians in clinical decision-making by helping to 
avoid unnecessary biopsies. The most well-established of these tools is the 
PC risk calculator from the ERSPC, which is used for men aged 55–74 years 
and is based on data from the Dutch section of the ERSPC. This method was 
developed using multivariable logistic regression analysis (150), and external 
validation has been performed using data from the Swedish (Göteborg) and 
Finnish sections of the ERSPC (151). This risk calculator has six levels 
(designated RC1–6) created using different logistic regression models, and it 
is available online for both doctors and patients (www.prostatecancer-risk 
calculator.com). RC1 considers family history, age, and voiding symptoms. 
RC2 uses PSA levels to predict the necessity of future investigation. RC3 and 
RC4 include prostate volume and DRE findings (which can be used for men 
with no previous biopsy or men with a benign result); inclusion of prostate 
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volume enhances the estimation of the risk of significant PC (152). A 
possible inclusion of the PHI blood test has also been evaluated (153) and 
seems to slightly improve the predictive capability. RC5 calculates the 
probability to have an indolent PC. RC6 is the most recent one, calculating 
the future PC risk over the next four years (based on family history, age, 
PSA, DRE and previous biopsy status). 
Genomic testing for localized PC 
Several genomic tests are available for men who have an established PC 
diagnosis, and these analyses are not diagnostic tests. Prolaris®, Decipher®, 
and OncotypeDx® can all be used for prognostic risk stratification and to aid 
treatment decisions (154). All three of these tests can be used to analyse 
prostate tissue (tumour cells in prostate biopsy). The Prolaris and Decipher 
tests can be performed after radical prostatectomy in cases in which 
secondary therapy can be considered. OncotypeDx provides an individual 
risk score that can be used in combination with other clinical data, and it is 
marketed as “the only test developed specifically for men deciding between 
active surveillance or curative treatment” (155). Unfortunately, these test are 
rather expensive; OncotypeDx costs approximately $4,200, although some 
researchers claim that substantial savings can be made as a result of the 
increase in uptake of active surveillance (156).  
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1.5 SCREENING 
The concept of screening entails the use of a simple and preferably 
inexpensive test that can classify a large number of individuals as either 
likely or unlikely to have the disease that the test is intended to detect. The 
main purpose of screening is to reduce mortality, although it can have other 
favourable effects as well. The use of screening as an approach to cancer 
control is controversial, and various benefits, costs, and potential adverse 
effects of screening programmes have been discussed for years (157). There 
are chiefly three types of screening: testing that can be applied to individuals 
requesting such evaluation (opportunistic testing); testing of high-risk 
individuals (selective screening); testing of the community as a whole 
(population-based screening). All individuals who participate in organized 
screening programmes are offered the same services and information.  
In 1968, Wilson and Junger (158) listed a number of criteria for evaluating 
screening tests and the effectiveness of a given screening strategy. Twenty 
years later, in 1988, the criteria for justifying a mass screening project were 
further developed by Hulka et al. (159) and can be summarized as follows:  
1. The disease investigated should represent a substantial burden at the 
public health level, and the early stages of the disease should be 
prevalent in the population. 
2. The early phase of disease should be detectable by a screening test. 
3. The screening test should have good performance with respect to 
sensitivity, specificity, and positive predictive value. 
4. Individuals with the disease who are diagnosed at an early stage 
should be more amenable to curative treatment than those diagnosed 
at more advanced stages. 
5. Early diagnosis and early curative treatment should reduce cause-
specific mortality. 
 
Thus it is assumed that early diagnosis and treatment will improve prognosis 
and reduce the risk of severe symptoms and/or the risk of dying due to the 
disease, and thereby affect the long-term outcome for those who participate 
in screening. However, even if a screening test can detect disease at an early 
phase/stage, that does not necessarily mean that all individuals subjected to 
screening will benefit. Those who participate and undergo the test with  
false-positive results will obviously not gain from participating, and indeed 
might suffer from adverse effects such as anxiety (160), the embarrassment 
and discomfort associated with diagnostic procedures, or adverse sequelae.  
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Also, many malignancies are discovered when signs and symptoms have 
become rather severe (and when cure is beyond reach), and thus the 
favourable outcomes of screening can only be achieved in asymptomatic 
participants. The optimal test should only detect cancers that lead to 
morbidity and mortality if untreated (and thus are still curable when 
diagnosed at an early stage). It is also possible that detecting cases that never 
develop symptoms can lead to overtreatment and the need for costly 
monitoring and active surveillance (161). This is particularly relevant for PC, 
in which the lead-time from diagnosis to symptoms can be very long. 
In addition to considering quality of life aspects, it is essential that the 
screening is simple to perform, cost-effective, and acceptable for both the 
subjects and the individuals performing the procedures (safe, acceptable and 
accurate). These aspects play a major role in the decision whether population-
based screening should be introduced. The number of individuals that have to 
be screened to prevent one death is defined as “the number needed to screen” 
(NNS) and is a measure of the effectiveness of the screening programme. 
Screening for other cancers 
Cervical cancer has a long period of pre-clinical disease. Screening with a 
relatively simple and cheap cervical (Pap) smear test (162) has been offered 
to women in Sweden since the late 1960s. The cervical screening programme 
represents a successful model of preventive care that has reduced the cancer 
incidence and cancer specific mortality dramatically (approximately 60–75%) 
in some countries. Primary prevention in the form of vaccination against 
HPV infection has been available in Sweden since 2012, and it is now part of 
the national vaccination programme offered to girls aged 11–12 years. Since 
2017, the screening guidelines call for a tests every third year between the 
ages of 23 and 49 years (HPV detection is an additional analysis in women 
30-49 years). For women between 50 and 64 years, screening takes place 
every seventh year. Approximately 700,000 cervical smears are taken in 
Sweden every year, and 150 deaths per year occur secondary to this disease. 
Studies have found that non-attenders constitute a high-risk group, and 
efforts have been made to improve participation rates and self-testing for 
HPV in Sweden (163).  
Lung cancer screening with chest X-rays is another example of efforts to 
identify disease at an early stage. However, there is no evidence that this 
strategy can detect the disease early enough to improve prognosis. One study 
showed no initial reduction in lung cancer mortality as the result of screening 
(164). Over the last few years, screening with low-dose chest computed 
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tomography (CT) has shown some mortality benefit, and CT screening 
programmes have been applied in some clinical settings (165). Tobacco 
cessation is an essential part of such a programme and is currently the only 
intervention that can prevent the development of disease. 
Breast cancer screening with mammography is conducted to find a tumour 
before a lump can be felt. The rates of overdetection and overtreatment 
associated with such screening are similar to those noted for PC screening. 
Many women will receive a diagnosis even if their cancers would not have 
led to death or aggressive disease. The authors of the Cochrane review from 
2013 found that screening resulted in very little or no reduction in the 
incidence of aggressive breast cancers (166). Those researchers stated the 
following: “If we assume that screening reduces breast cancer mortality by 
15% after 13 years of follow-up and that overdiagnosis is at 30%, it means 
that for every 2000 women invited for screening throughout 10 years, one 
will avoid dying from breast cancer and ten healthy women will experience 
anxiety and uncertainty for years because of false positive findings”. It has 
been proposed that advances in treatment and improved awareness among 
women have diminished the mortality reduction found in previous screening 
trials. Overdiagnosis is problematic, and little or no reduction in the incidence 
of advanced disease has been reported. 
Colorectal cancer (CRC) screening can be performed by faecal occult 
blood testing. Such screening has been reported to reduce CRC mortality by 
approximately 30%, but only when a positive test leads to more invasive 
procedures, such as colonoscopy, a method that enables examination of the 
entire colon and removal of pre-cancerous polyps. Other potential methods 
for early detection include CT colonography, video capsule colonoscopy, 
stool DNA testing, and double contrast barium enema. Most guidelines 
recommend that CRC screening for average-risk individuals be initiated at 
the age of 50 years, although several European programmes start at around 
age 60 (167). Most CRC patients are diagnosed between the ages of 65 and 
74 years, and individuals of African descent are reported to be at higher risk 
of this disease. Many guidelines recommend an upper age limit for screening 
varying from 70 to 75 years, because the associated harms may potentially 
exceed the benefits after this age. As for other screening programmes, 
adherence is crucial, and a less invasive method makes it easier for 
individuals to participate. Screening intervals, as well as the rank order of 
different tests/procedures, are more uncertain.  
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1.5.1 Screening for prostate cancer, a dynamic process 
The aim of screening men with PSA is to reduce morbidity and mortality 
from PC by detecting the disease at an earlier stage when it still is curable. To 
understand the concept of PSA screening, we must consider different phases 
of disease progression, as has been clearly illustrated by Törnblom et al. 
(168).  
First, there is a nondetectable preclinical phase (A) when cells transform 
into malignant cells and start dividing. Eventually, this transformation 
process will lead to an elevated PSA level, which, in a screening setting, will 
trigger intervention (biopsy). At this point, the cancer is in a preclinical, but 
detectable phase (B), also known as the sojourn time. The delay time (C) 
can be described as the period spanning from when the cancer is in a 
detectable preclinical phase up to diagnosis (in this case the delay time is 
shorter as an effect of screening). 
 
Figure 9. Prostate cancer progression is a dynamic process that occurs over time. Illustration 
by Magnus Törnblom, reprinted with permission.  
Thus, the screening regimen can detect the tumour in an earlier phase 
(compared with diagnosis based on clinical symptoms), and the time gained 
by such early detection is often referred to as lead time (D), whereas E 
represents the time period from diagnosis (due to clinical symptoms) until 
death and censoring. When interpreting the results of screening, it is 
necessary to be aware of an aspect called lead-time bias (if survival is 
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estimated). Detecting PC at an earlier stage can result in what seems to be an 
extended survival (F) after diagnosis. For the individual, this means that the 
PC is diagnosed earlier, but the time of death might not be affected (no actual 
survival benefit exists). Lead time can be estimated by comparing the time 
difference in PC incidence in screened men and controls (ratio of detection 
rate at screening to the expected incidence), and such estimates are essential 
for defining an optimal screening interval. However, lead time is not a fixed 
value, because different types of PCs have very different growth rates. The 
most common approach is to estimate the median lead time, although the 
optimal would be to understand the distribution of lead time in the cancers 
detected by screening. Longer lead times indicate higher risk of 
overdiagnosis (at least in an elderly population), whereas shorter lead time 
implies low sensitivity of a screening programme. PC screening has shown 
that many cancers are incurable long before they are clinically detected (169). 
Figure 10 illustrates plausible characteristics of an unscreened population. 
 
Figure 10. Prostate cancers detected during the first screening round can be heterogeneous. 
Some are already beyond the “window of cure”, and others have a very slow growth rate and 
can be regarded as overdetected. 
Cancers detected during the first screening round (prevalence screening) can 
be very heterogeneous. Some cases are already incurable, and others have a 
very slow growth rate and can be regarded as overdiagnosed. However, the 
situation immediately after conclusion of an ideal prevalent screening will 
have no cancers in the detectable phase. As time proceeds, new non-
detectable cancers will grow and become detectable, but their features will 
differ. Fast-growing cancers will reach the detectable phase more quickly 
than slow-growing cancers, and the distribution between fast and slow-
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growing cancers will differ from the situation seen in prevalent screening 
(Figure 11). This model outlines some important features of PSA screening. 
 
Figure 11. Cancer detected at repeat screening rounds are more homogeneous, few are 
incurable, and the proportion of slow-growing PCs is lower. 
• The risk of detecting slow-growing and probably insignificant 
cancers is largest during the initial screening round. 
• Many incurable cancers are detected during the initial screening 
round. 
• The proportion of fast-growing cancers in a curable phase is larger in 
repeat screening rounds. 
• Every screening round detects new fast-growing PCs (i.e., potentially 
lethal cases) that are still in a curable phase. 
• The lead time of clinically important cancers is unknown but is 
probably much shorter than estimates based on all PCs detected 
during screening. 
The weakness of this model is that the first PSA screening round does not 
detect all PCs in the curable and preclinical phase. Indeed, it appears that it 
takes approximately three screening rounds to detect all prevalent cancers 
(170). In any case, this model can explain many of the discrepancies found 
between different screening studies. This model also implies that PSA testing 
on only one occasion will offer little benefit but still entail a high risk of 
overdiagnosis. In short, in programmes limited to a single testing, the small 
proportion of fast-growing cancers that are cured will “drown” in the large 
population of cases that are either overdiagnosed (slow-growing) or detected 
too late. There is no biological reason to hypothesize that PSA screening only 
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once would be particularly beneficial in reducing PC mortality. On the 
contrary, a programme with only one screen may be harmful as a large 
proportion of very slow growing PCs will be detected (and result in 
overdiagnosis) (171). To catch the fast growing and potentially lethal cancers 
in a curable stage, PSA screening has to be repeated. Thus screening men 
with PSA is a dynamic process, not a static once-in-a-lifetime intervention. 
1.5.2 Randomized screening trials 
To evaluate the effect of screening, two large-scale population-based studies 
were designed in the 1990s: the ERSPC in Europe and the PLCO screening 
trial in the United States (172). The ERSPC was started in 1994, and it 
represents the largest trial for screening of PC, performed in eight European 
countries: the Netherlands, Sweden, Finland, Belgium, Italy, Spain, 
Switzerland and France. Although the protocols applied in the ERSPC 
differed between the eight countries, in generally men were randomly 
allocated either to a screening group that offered PSA testing every 2–4 
years, or to a previously unscreened control group with no invitation to PSA 
testing. The control group was exposed to opportunistic screening (173) 
(contamination 23–40% after 13 years). 
The core age group in the ERSPC was 55–69 years, and in Göteborg we also 
included men aged 50–54 and used a 2-year screening interval. Our centre in 
Göteborg and several other ERSPC centres independently publish results that 
are available at www.erspc.org. As mentioned above, the ERSPC is the 
largest screening trial for PC, randomizing 73,000 men to screening and 
90,000 to serve as controls (all men 50–74 years of age). Men included in 
Italy, Finland, and Sweden, were identified from population registers and 
randomly assigned to the screening or control arm before giving informed 
consent. In the other countries, men first provided consent and the men who 
provided consent were later randomized to the screening or the control group. 
The primary outcome was the rate of death from PC. In 2014, data from 13 
years of follow-up in the ERSPC showed a 21% relative decrease in PC 
mortality in favour of the screening arm (173).  
Such a reduction was not seen in the US PLCO screening trial (174), most 
likely due to the very high levels of PSA testing in the control arm in that 
study. PSA testing was introduced in the US in 1988, and by 1994 most men 
over the age of 65 years had been tested. Between 1993 and 2001, men were 
invited to participate in the PLCO initiative, and those assigned to the 
screening group were offered annual PSA testing for 6 years and DRE for 4 
years. Self-reported PSA testing rates in the control arm ranged from 40% to 
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52% (during the first and the last year, respectively). Participants in both 
study arms were pre-screened with PSA before entering the study. However, 
after adjusting for differences in implementation and setting, the data from 
both the ERSPC and the PLCO do not indicate that the efficacy of screening 
(relative to no screening) differed between these two trials (175). 
The Norrköping study was initiated in 1987, and data on 20-years of follow-
up in that trial were published in 2011 (176). A total of 1,494 men were 
invited to screening, and 7,532 were allocated to the control group. The 
interventions were screening every 3 years versus control (i.e., not invited). 
The first and second screening rounds included only a DRE (i.e., no PSA 
test), whereas the third and fourth rounds included both a DRE and a PSA 
test. Biopsies were performed if the DRE was abnormal or if the PSA level 
was ≥ 4 ng/mL. After 20 years of follow-up, the death rate from PC did not 
differ significantly between the men in the two arms. The Norrköping study 
has been criticized for both its statistical presentation, low power and the use 
of DRE as a screening tool (177). Furthermore, information on the 
investigation was distributed via television, radio, and newspapers, which 
might have had an impact on men’s decision to participate in the study. 
Trial 
 
Size of study 
population 
(screening +  
control) 
 
Target  
age group 
(years) 
 
Screening 
tests used 
 
Participation 
rate 
 
Follow-up 
(years) 
 
No. of prostate 
cancer deaths 
(screening +  
control) 
 
RR for prostate 
cancer mortality 
(95% CI) 
 
        
ERSPC 72,891 + 89,352 55–69 PSA 83% 13 355 + 545 0.8 (0.7–0.9) 
PLCO 38,340 + 38,343 55–74 DRE, PSA 85–89% 15 255 + 244 1.0 (0.9–1.2) 
Norrköping 1,494 + 7,532 50–69 DRE, PSA 70–78% 20 30 + 130 1.2 (0.8–1.7) 
Stockholm 2,400 + 24,772 55–70 DRE, TRUS, 
PSA 
74% 20 86 + 857 1.1 (0.8–1.3) 
Quebec* 31,133 + 15,353 45–80 PSA, DRE 24% 11 153 + 75 1.0 (0.8–1.3) 
CAP 189,386 + 219,439 50–69 PSA 40% 10 549 + 647 0.9 (0.7–1.3) 
 
Table 5. Randomized prostate cancer screening trials. Note: in the Quebec* study the authors 
reported a reduction in PC mortality that could not be found when data were re-evaluated 
according to the intention-to-screen principle (178). 
The Stockholm study was initiated in 1988 and recently published a report  
presenting data on its 20-year follow-up of PC outcomes (171). Men aged 
55–70 years and living in the Stockholm area were included in a screening 
arm (n = 2,374) or in a control arm (n = 24,772) for comparison. The 
intervention was “one screen only” versus no screening, and the screening 
consisted of DRE, PSA testing, and TRUS. Biopsies were performed if a 
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participant had abnormal DRE findings and/or an abnormal TRUS. A repeat 
ultrasound was performed if the PSA level was ≥ 7 ng/mL, but the PSA 
threshold demanding biopsy was high (≥ 10 ng/mL). With this study design 
(i.e., a single intervention in a previously unscreened population), many of 
the PCs detected were in an advanced stage at diagnosis, referred to as 
“prevalent cancers”. Hence no effect on PC mortality was found in the 
Stockholm study (RR 1.05, 95% CI 0.83–1.27), but an excess incidence of 
10–20% remained after 20 years. This investigation was initiated primarily to 
evaluate a PC detection strategy, not mortality. Neither the screening 
procedure nor the treatments used were state of the art, and the external 
validity can be considered low (not generalizable to the modern setting). A 
null result from a one-time screening is not unexpected, even with such a 
long follow-up period.  
The Quebec study of PC screening recruited men aged 45–80 years who 
were identified in electoral rolls and allocated 2:1 to a screening and a control 
arm. Annual screening with the combination of DRE and a PSA test was 
offered. The cut-off for further biopsy was set at PSA ≥ 3 ng/mL and/or 
abnormal DRE. Follow-up screening rounds included a PSA test, and TRUS 
biopsies were performed if the PSA level was ≥ 3 ng/mL (for the first time), 
or if PSA increased > 20% compared with the previous screening round. The 
outcomes in participants after 11 years of follow-up were reported in 2018 
(179). Only 24% of the 31,133 men who were invited to undergo screening 
actually participated, and this low adherence rate reduces the power of the 
study. The Quebec trial has also been criticized for the long time lag between 
randomization and screening (on average 3 years), and also for the crossover 
between groups (180). More than 7% of the men in the control arm 
underwent PSA screening, and the results were not analysed according to the 
intention-to-screen principle. 
Data from the Cluster Randomized Trial of PSA testing for Prostate 
Cancer (CAP) was recently published in the Journal of the American 
Medical Association (181). CAP can be described as a large and well-
designed cluster-randomized study conducted in the United Kingdom. In 
short, primary care units were randomized to invite men to a single PSA test. 
PC specific mortality was used as end-point, and more than 400,000 men, 
aged 50–69 years were recruited between 2001 and 2009. After a median 
follow-up of 10 years no difference was found between men in the screening 
arm and men in the control arm (RR 0.96, (95% CI; 0.85–1.08). More than 
50% of the PC deaths in the intervention arm occurred during the first 7 years 
of the study. Two important aspects should be mentioned. First, it is highly 
unlikely that PSA screening would have had an effect on these cases, given 
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the biology of the disease; many of these cancers were already “beyond the 
window of cure”. Second, the follow-up was too short, considering the long 
natural history of PC. Our data from the Swedish section of the ERSPC 
(presented in Paper III) show that screening had no major effect on PC 
mortality during the first 10 years; a reduction in mortality was observed after 
approximately 12–14 years. 
Both the CAP trial and the Stockholm study used a single PSA measurement, 
which, as argued before, is a very ineffective way to screen men for PC. Our 
findings (Paper III) indicate that the first screening round detects more 
advanced and incurable PCs. So, screening men at only one occasion result in 
either a benign biopsy or detection of a prevalent cancer (which often is too 
late to cure). Such cancers “dilute” the difference between screened men and 
controls, and thus the true effect of screening is diminished (discussed in 
Paper III). Therefore, it is irrational to assume that a single PSA measurement 
can be beneficial in reducing PC mortality. Although this approach does 
identify advanced and incurable cancers, it misses the chance of later 
detection of progressive disease (as the men in the cohort grow older). On the 
other hand, a single PSA test in midlife is a valuable predictor of future lethal 
PC (182) and can be used in conjunction with other factors (age, 
comorbidities) to stratify risk and intervals for re-testing (183, 184). 
Commentators discuss the evidence as to whether PSA-based screening 
actually reduces PC-specific mortality and some base their arguments on the 
findings from studies where PSA was used as a single intervention. 
In September 2018, Ilic et al. published a systematic review and meta-
analysis (185) of five major trials (all mentioned above): the ERSPC, the 
PLCO trial, the Quebec study, the CAP and the Stockholm study. Ilic and 
colleagues pooled data from these very different and heterogeneous trials and 
concluded that “PSA screening yields, at best, only a small benefit in PC- 
specific mortality, but does not reduce overall mortality”. These authors also 
emphasized that “this small benefit should be weighed against the potential 
complications related to the biopsy and long-term side effects from 
treatment”. Indeed, weighting the benefits of screening against the potential 
harms, is of the outermost importance, when discussing PSA testing with 
men, but the main conclusion drawn in this review can be questioned. 
Guidelines for conducting systematic reviews and meta-analyses mandate 
that only studies that are conceptually similar should be included in a 
quantitative synthesis, otherwise the findings will not be applicable to clinical 
practice and may misinform lay audience. The Cochrane Handbook (186) 
advises against combining ‘apples with oranges’ and states: “if studies are 
clinically diverse, then a meta-analysis may be meaningless and genuine 
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differences in effects may be obscured” and “meta-analyses of studies that 
are at risk of bias may be seriously misleading.” The five studies that were 
assessed did not address the same scientific question. Furthermost, using 
overall mortality, which has a power that is too low to detect a difference 
between trial arms, is not a valid end-point. A trial of cancer screening with 
such endpoint would require well in excess of 500,000 individuals, which is 
why no such study has ever been initiated. An article by Carlsson et al. (187) 
discusses a number of important weaknesses related to this type of meta-
analysis, and several of the errors mentioned by these authors can also be 
applied to the above-discussed review by Ilic et al. 
In summary, evaluating screening studies and the outcomes of PSA screening 
is perplexing and results are often misinterpreted. Besides the actual effect on 
the population, consequences on health economy must be considered when 
discussing screening strategies. Nevertheless, negative effects of not having a 
strategy (as is the situation of today with the on-going opportunistic testing) 
are difficult to overlook and neither a good option. 
1.5.3 Negative and positive effects of PC screening 
Negative effects of PC screening 
Screening with a PSA test can generate false-positive results, because the 
level of PSA can be elevated due to any disease of the prostate (i.e., BPH and 
prostatitis. False-positive findings lead to additional PSA tests and 
unnecessary biopsies. This can be very stressful for the individual, and some 
men will also suffer from unwanted side-effects from diagnostic procedures 
(infections, haematuria etc). The main objective of screening is to reduce 
mortality and “the benefit-versus-harm balance” must be continuously 
assessed, both on a group and individual level. 
Both the ERSPC and the Göteborg study found that PSA screening resulted 
in a significant reduction in PC-specific mortality, but no trial has shown that 
men undergoing screening have an advantage with respect to overall survival. 
As discussed before, overall mortality is the wrong endpoint and a 
reduction in PC-specific mortality is a more appropriate outcome measure, 
which should be weighed against the harms of screening.  
Many men harbour a localized and indolent PC, and it has been estimated 
that up-to 25–50% of all screen-detected cancers are overdiagnosed (91, 
188). Overdiagnosis and overtreatment are the major concerns, because 
they are associated with negative aspects that reduce quality of life, such as 
impotence and incontinence. The term overdiagnosis is usually applied to 
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specify detection of a tumour that never would have caused any symptoms. 
Overdiagnosis and overtreatment constitute the main reasons why PC 
screening is not generally recommended (189). Concentrating screening to 
those who benefit the most is therefore something we strive for.  
With the emergence of many novel biomarkers (and biomarkers combined 
with clinical examination and imaging), it is also necessary to consider the 
costs of screening and PC treatment. Choosing what biomarker to use and 
selecting the “optimal” target population can be challenging tasks. Today, 
urologists and clinicians are not always familiar with the financial impact that 
their recommendations have. In an editorial published in 2016, Eggener et al. 
wrote the following: “Nowadays, it is possible for a man to undergo a parade 
of shockingly expensive tests, a MRI-based fusion biopsy, tissue-based 
genetic evaluation of the cancer, robotic surgery or proton-beam therapy, 
immunotherapy, multiple novel androgen-blocking therapies, multiple 
chemotherapy regimens, radium-based bone-targeting agents, and 
bisphosphonate or receptor activator of nuclear factor-kappaB (RANK)-
ligand supportive bone care.”(190). This statement describes the direction in 
which PC care is being developed. There are many options for patients with 
PC, associated with uncontrollable costs.  
On a population level, gaining quality-adjusted life years (QUALYs) might 
favour implementation of a screening programme, but many men will also 
experience adverse effects and harm following treatment. For the individual, 
this can lead to a miserable life with years of suffering. A study using 
microsimulation models found that the positive impact of screening was 
diminished by loss of QALYs resulting from long-term side effects (191). 
Positive effects of PC screening 
PSA screening increases the chance of detecting PC, while the disease is still 
curable. Early detection of PC also results in a reduction of metastatic 
disease, which was found to be approximately 40% in men who were 
screened in the ERSPC (169). Bone metastases are often very painful for the 
individual and causes a number of clinical problems. Furthermore, 
diagnostics and treatments are also very costly and have side-effects.  
Large RCTs have demonstrated that PSA screening reduces PC specific 
mortality by 25–32% (75, 192), findings that are confirmed by the results 
reported in Paper III. The ERSPC trial has shown a decline in the NNI and 
the NND over time (173); the number of men who need to be invited and 
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diagnosed to save one man. With a longer follow-up time the absolute 
number of avoided deaths from PC increased.  
PSA testing is easily accessible in Sweden and the public awareness 
contributes to unorganized and widespread opportunistic testing. More than 
50% of all PC cases in this country are diagnosed this way (193), even 
though it has been shown that an organized screening is more effective. 
According to results from the Göteborg screening trial opportunistic PSA 
testing in the control arm only resulted in an absolute reduction in PC- 
specific mortality of only 0.2% (compared with 0.73% in the screening arm) 
(194). Men who are tested outside the programme are recommended different 
follow-up regimens, and some with high PSA levels are not followed at all. 
Another aspect of PSA testing is that some men prefer to know if they have 
PC. Studies assessing anxiety levels in men offered PSA screening have 
noted that “seeking peace of mind” was the motivation mentioned most 
often by those who were anxious but still underwent screening (195). 
1.5.4 Screening approaches 
Routine PSA-based screening of asymptomatic men is one of the most 
controversial topics in urology and preventive medicine. The 
recommendations are confusing both for men who themselves request testing, 
and for physicians who rely on current guidelines. Even guideline groups and 
other experts are unable to agree on, nor decide, what strategy to use (196). In 
2012, the US Preventive Services Task Force provided a statement with a 
very stringent recommendation against PSA screening (197), which they 
later changed to a shared decision making process. Other guidelines have 
focused on a more individual approach, considering when to terminate 
further PSA screening (i.e., a stop age) and on other ways to reduce harm.  
Today, Lithuania and Kazakhstan are the only two countries in the world that 
offer an organized population-based screening programme for PC (198, 199). 
The programme in Lithuania was initiated in 2006, and it was originally 
suggested that all men aged 50–74, as well as men aged 45–49 with a family 
history of PC, would undergo PSA testing once a year; in 2008, the screening 
interval was changed to every second year due to logistical problems and 
high costs. In Lithuania, the PC incidence increased dramatically in  
2005–2009, when more than 15,000 men were diagnosed with the disease 
(compared with 2,200 cases detected during the period 1990–1994 (200).  
The full effect on PC mortality is still to be awaited, but it is obvious that, in 
general, overdetection is a huge problem with their screening strategy. 
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The Swedish National Board of Health and Welfare does not recommend a 
countrywide population-based PSA screening programme for men. However, 
there is an ongoing investigation that is being performed to analyse and make 
suggestions regarding whether screening should be organized in regional 
projects, and if so, how that can be accomplished. Both the AUA (116) and 
the EAU recommend that PSA testing should be offered to “well-informed 
men” who have insight into the benefits and possible harms of screening 
(115). The EAU guidelines also recommend the use of what are known as 
risk calculators to evaluate the individuals’ risk of PC and thereby avoid 
biopsy in some men.  
In 2016, Carlsson and Roobol published a summary on currently available 
recommendations on PC screening (201). They conclude that “new 
biomarkers, multiplex screening and PSA based risk stratification at early age 
can shift the ratio of benefits and harms”. A “one-size-fits-all” solution might 
no longer be the right approach. Age, health status and PSA level are 
therefore important when considering if and when to screen.  
Crawford et al. (202) suggested that the effect on PSA testing depends on 
other comorbidities: Men who have other illnesses (e.g., heart disease and 
diabetes) in addition to PC are more likely to die from those conditions, than 
from PC. Theses authors came to the following conclusion: “Selective use of 
PSA screening for men in good health appears to reduce the risk of PC-
specific mortality with minimal overtreatment”. Furthermore, the man needs 
to be fully informed and comprehend what consequences screening might 
have. Most guideline groups recommend shared decision-making where the 
patient and doctor discuss pros and cons of screening. To aid in this dialogue, 
a risk-stratified approach aimed at primary detecting lethal PC has been 
suggested. 
One approach is to use a baseline PSA for risk-stratification. Vickers and 
colleagues have assessed data from the Malmö Preventive Project cohort to 
study outcomes in 20,000 men (203). PSA levels in these men were analysed 
more than 25 years after enrolment in the project and associations between 
initial PSA and later PC were calculated. It was possible to define a baseline 
PSA (specified by age) and to approximate future risk. Men who were in 
their 40s had a 10-fold risk of metastatic disease if their initial PSA level was 
> 1.6 ng/mL (compared with a level of > 0.6 ng/mL). The majority of men 
aged 40–45 years had low PSA values (< 1.0 ng/mL) and a very low risk of 
PC death within 25 years. Vickers and co-workers concluded that having a 
PSA test in early midlife can identify a small group of men at increased risk 
of developing aggressive disease several decades later, and these men need to 
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be closely monitored. Furthermore, these investigators deduced that men at 
very low risk, with PSA values of < 1.0 ng/mL could wait a few years and 
return for screening in their early 50s, and again at age 60 (if PSA was 
unchanged). Others have proposed that when PSA exceeds 1.0 ng/mL, testing 
every 2 or 4 years should be recommended (204). The mentioned suggestions 
indicate that the main focus should be on men who are in the highest 10% of 
PSA levels at around the age of 50.  
In 2015, a report from the Swiss branch of the ERSPC proposed the use of a 
“PSA pyramid” for men with initial PSA levels below 3 ng/mL (205). This 
suggestion emanated from an evaluation of data on 4,300 men aged 55–70 
years who participated in a screening programme with PSA testing every 4 
years. In that study, baseline PSA was found to be a strong predictor of future 
PC and aggressive disease. Half of all the men who were assessed had an 
initial PSA of < 1.0 ng/mL, and these men also had a very low risk of 
developing aggressive PC within 8 years (0.21%). The authors proposed the 
following: men with an initial PSA of < 1.0 ng/mL can be safely retested 
after 8 years; men with PSA 1–1.99 ng/mL can be retested after 4 years; and 
men with PSA in the range 2–2.99 ng/mL require needs further risk 
stratification. 
Five simple and straightforward “golden rules” for PSA screening have been 
proposed by Vickers and colleagues (206): 
1. Get consent. Do not take a PSA test without discussing it with the 
patient. A PSA test is sometimes added when doctors order blood 
work as part of a routine health check-up. Information about harms 
and benefits should always be given. 
2. Do not screen men who won’t benefit. Men who are age 80 and have 
multiple comorbidities or men who have a life expectancy less than 
10 years are very unlikely to benefit from taking a PSA test. Most 
recommendations use age 75 as a stopping point.  
3. Do not biopsy without a good reason. A majority of men with 
slightly elevated PSA do not have PC and few men with low PSA 
have aggressive PC (207). 
4. Don’t treat low-risk disease. Many screen-detected PC have low-risk 
features (GS < 7) and can be managed with active surveillance (208). 
5. If you have to treat, do so at a high-volume centre. Experienced 
surgeons have higher cure rates and fewer complications. Also, they 
have better outcomes for urinary and erectile function (209). 
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The authors conclude that “the benefit-harm ratio of PSA screening can 
be improved by avoiding screening, biopsy and treatment in men who are 
unlikely to benefit” 
1.5.5 Public attitude towards screening: what do men want? 
In 2012, the US Preventive Services Task Force recommended against PSA 
screening, which caused a public outcry, and the new guidelines were met 
with resistance by many men in the United States (210). Likewise, the field 
of breast cancer screening has provided findings suggesting that even if 
people are informed that screening is associated with potential overdetection 
and possible harm, they are willing to take the chance that screening can be 
beneficial (211).  
People are often prepared to take part in activities that have (or might have) a 
positive impact. Such behaviour can also result in irrational decisions and a 
desire to “take action”, regardless of the consequences. In psychology, this is 
called “action bias” or “error of commission” (212) and it is discussed at 
length in a paper recently published by Scherer et al. (213). These authors 
explored the public enthusiasm for cancer screening, and they surmised that 
the extensive interest in PSA screening might be due solely to lack of 
knowledge about the risks. Participants in that study were told the following: 
“There is a new test to screen for prostate cancer, and this test uses 
diagnostic technology to look for abnormalities that may be early stage 
cancer”. The subjects were also given this information: “One problem with 
the test is that it may detect cell abnormalities that will never develop into 
dangerous PC. This might lead to unnecessary treatment and harms 
(physical, emotional, and financial). The test can also fail to detect 
dangerous cancers”. A majority of the men who were asked if they were 
willing to take the test said that they would have done so, even knowing that 
the results obtained could neither help prevent death due to PC nor extend 
length of life. Scherer and colleagues concluded that many people perceive a 
possible advantage of receiving health information, even if it provides very 
uncertain or no survival benefit. 
Another, recent evaluation of the preferences of screening subjects was 
conducted by Vernooij et al. (214) as a systematic review of 11 studies, and 
the results revealed considerable variation in men’s values and preferences. 
Several of the vetted studies reported that men were willing to accept 
considerable risk of harms (e.g., unnecessary diagnostics, impotence, and 
incontinence) to accomplish even a small reduction in risk of PC death. Thus, 
Vernooij and co-workers came to this conclusion: “The variability of men’s 
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values and preferences, particular to the degree that their information needs 
are met, reflect that the decision to screen is highly preference sensitive”. 
Regardless of whether we are proponents or opponents of screening, it is time 
to admit that PSA screening is something that men request. As mentioned 
previously, many men in Sweden have a PSA test on their own initiative 
(opportunistic testing), even if there is no national recommendation to guide 
them in this decision. Such ambiguity makes it difficult to allocate the right 
resources to PC care. Therefore, politicians and healthcare providers must 
have a better contingency plan to ensure correct handling of this issue. 
  Maria Frånlund 
 52 
2 AIM 
The overall objective of the studies underlying this thesis was to assess the 
long-term outcome of a PSA-based PC screening programme in Sweden. The 
specific aims and research questions were as follows: 
PAPER I 
To investigate whether voiding symptoms in men with an elevated PSA  
(≥ 3 ng/mL) are associated with the risk of PC. 
PAPER II 
To evaluate the risk of PC in men with an initial PSA level below 3 ng/mL 
and determine whether the free-to-total PSA ratio can be a useful prognostic 
marker in this PSA range. 
PAPER III 
To compare differences in PC incidence and PC-specific mortality after 22 
years of follow-up, and also to consider how PC screening can be improved. 
PAPER IV  
To evaluate the future outcomes in men terminating the screening program at 
stop age (≥ 67 years) and to ascertain whether some of these men might need 
prolonged PSA screening. 
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3 PATIENTS AND METHODS 
3.1 STUDY POPULATION  
The Göteborg Randomized Screening Trial 
The four papers included in this thesis (designated I–IV) describe our 
investigations based on data from the Göteborg randomized population-based 
PC screening study, which was initiated in 1994 and was approved by the 
Ethics Committee of the University of Göteborg, Sweden, and registered with 
controlled-trials.com (no. ISRCTN54449243). 
According to the Swedish Population Register, as of December 31, 1994, 
32,298 men born between 1930 and 1944 (i.e., aged 50–64 years, median 56 
years) were living in the city of Göteborg (total population 440,000). Of these 
32,298 men, 20,000 were randomly assigned to either a screening or a control 
group (in a 1:1 ratio). The randomization procedure was performed at the 
Department of Statistics, University of Göteborg. No informed consent was 
needed for men in the control group. Men in the screening group were invited 
for biennial PSA testing; men in the control group were not invited (although 
they did have access to opportunistic PSA testing). A total of 106 men were 
excluded (55 in the screening arm and 51 in the control arm) for the 
following reasons: 55 were already diagnosed with prevalent PC; 35 were 
deceased; 10 had emigrated; five had moved away from West Sweden (these 
men were still in the Population Register at the time of randomization); and 
one man assigned to the control arm was not willing to participate. 
Men were invited to join the study starting in January 1995. In 1996, the 
investigation became connected with the large ERSPC, but no changes were 
made in the Göteborg protocol when this association was established. Figure 
12 shows the screening algorithm used in the Göteborg Randomized 
Screening Study. 
Every second year, men in the screening group received a letter describing 
PSA testing and its advantages/disadvantages, together with an invitation to 
participate. The upper age limit for invitation was 67–71 years (median 69 
years). The oldest men received three invitations before reaching the upper 
age limit, whereas the youngest men had 10 invitations. The last screening 
round took place during 2013–2014. No invitations were sent to men in the 
control group. 
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Initially, the PSA cut-off that led to further urological assessment was set at 
3.4 ng/mL, but this level was changed twice to be consistent with other 
ERSPC sites and to deal with issues related to calibration of the PSA assay 
(Prostatus Total/Free PSA-Assay, Perkin-Elmer, Turku, Finland). The actual 
cut-off was 3.4 ng/mL during screening rounds 1–2 (1995–1998), 2.9 ng/mL 
during rounds 3–5 (1999–2004), and 2.5 ng/mL during rounds 6–10 (2005 
and onward). DRE, TRUS, and prostate biopsies were recommended for men 
with a PSA value that exceeded the cut-off level. Sextant biopsies were 
performed up to 2009, after which a 10-core biopsy was used in the study 
protocol. Men with a benign biopsy or with a PSA of < 3 ng/mL were re-
invited for PSA testing after 2 years. Men who were identified as having PC 
were offered consultation and treatment by physicians working at the 
Urology and/or Oncology Department at Sahlgrenska University Hospital. 
Some men were diagnosed with PC outside of or after leaving the study 
(interval cancers or after stop age). These cases are referred to as non-screen 
detect PCs. Available and relevant medical information regarding tumour 
stage, treatment, PSA relapse after treatment, and metastases was 
continuously entered into the database, and every third month information 
and data were linked to the Regional Cancer Register and the Swedish 
Population Register. Since 2009, data have also been linked to the Swedish 
Cancer Register, which has very high completeness (> 96%) (215). Thus, 
information on PC diagnosis, mortality, and emigration has been added 
continually to the study database in this manner. For all deceased men, a copy 
of the death certificate was obtained. The cause of death (COD) in men with 
PC was determined by an independent COD committee, according to a flow 
chart (216). Three members of the committee reviewed the medical 
information on deaths in a blinded and independent manner. 
The 10th and final screening round was completed 2014, at which time all 
age cohorts had reached the upper age-limit for invitation. Nevertheless, the 
study database continues to be regularly updated on PC diagnoses and deaths 
(in both study groups). Cases in which information on deaths is lacking and 
the COD is uncertain are labelled as “pending” in our database. 
Prostate Cancer Screening: Outcomes and Risk Prediction   
 
 55 
 
Figure 12. Consolidated Standards of Reporting Trials (CONSORT) diagram showing the 
screening algorithm of the Göteborg randomized population-based prostate cancer screening 
study. Last follow-up on December 31, 2016. 
Paper III presents the outcomes after 22 years of follow-up. For all men who 
had moved away from West Sweden before their last invitation was sent, the 
latest test results were excluded from the analysis. Thus, any cancers that 
were diagnosed after that timepoint were not included in the assessment. 
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3.2 REGISTERS  
Sweden has a long tradition of collecting epidemiological data. Use of the 
unique personal identity number enables researchers to link data from studies 
obtaining information from several registers at the same time. 
The Swedish Cancer Register (SCR) 
The SCR is the oldest health register in Sweden (established in 1958). It 
covers the entire population and is now divided into six regional cancer 
registers, administrated by the Regional Cancer Centres (RCCs). Quality 
assessment is performed by the Swedish Board of Health and Welfare. It is 
mandatory for all healthcare providers to report new cancer cases to the SCR, 
which covers 96% of all cancers (215). About 64,000 malignant tumours are 
diagnosed every year. The register contains data on the patient (personal 
identity number, age, sex, place of residence) and medical aspects (tumour 
location, histological type, TNM stage, date of diagnosis, reporting hospital/ 
pathology department, and identity number for the tissue specimen), as well 
as follow-up data (date of death, cause of death, and date of emigration). 
The Swedish Cause of Death Register 
Since the early 1960s, the Swedish Cause of Death Register has compiled the 
following data on deceased individuals: sex, date of death, age at death, place 
of death, and cause of death coded according to the International 
Classification of Diseases (ICD). The data in this register are updated on an 
annual basis. When a person dies in Sweden, a death certificate is first 
completed by a physician (or a nurse if the death was expected) and thereafter 
sent to the Swedish Tax Agency within 2 workdays. An additional COD form 
is also filled in (in some cases after an autopsy) and sent to the National 
Board of Health and Welfare within 3 weeks. The register contains data on 
~98% of all deaths. A study conducted in Göteborg found that Swedish death 
certificates for men with PC are highly accurate (217). Death certificates can 
therefore be used for endpoint evaluation in screening studies for PC.  
The Swedish Population Register 
The population register in Sweden was managed by the Church of Sweden up 
to 1991, and since then it has been administered by the Swedish Tax Agency. 
This register contains information on personal identity number, place of birth, 
civil status, children/adoptions, address, citizenship, immigration to Sweden, 
and death and place of burial. Furthermore, valuable information about 
migration within Sweden and emigration to other countries can be obtained 
from this register when conducting screening studies. 
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3.3 STATISTICAL METHODS  
Several different statistical methods were used in the present investigations. 
In the Göteborg screening trial, data were collected prospectively and 
analysed longitudinally. A short overview of the methods applied is 
presented below. 
Survival analyses: time-to-event assessment 
In PC studies, survival analyses can be performed to achieve the following: 
• Visualize survival curves and estimate cumulative incidence 
(e.g., Kaplan-Meier [KM] and Actuarial methods). 
• Describe the effect of covariates on survival (e.g., Cox 
proportional hazard regression). 
• Compare survival curves of different groups (e.g., log-rank 
test). 
The survival analyses discussed in this thesis focused on the time between 
entry into the study and a subsequent event (e.g., PC diagnosis or PC death). 
However, this event will not have occurred in some of the men within the 
study period, but these subjects can be censored for other reasons, for 
example: 
• Lost to follow-up during the study period (moved from West 
Sweden or emigrated to another country). 
• Death from other causes.  
The Kaplan Meier (KM) method (218) was applied in two of our studies 
(Paper II and IV). The KM estimator of the survival function is a non-
parametric statistic used to estimate the survival function (i.e., the probability 
of being event free at a certain time). The survival probability is calculated as 
the number of men who are event free divided by the number of men at risk. 
The KM analysis uses exact times for each outcome in contrary to the 
actuarial method (see next page). Men who are censored are no longer at risk. 
KM curves and estimates of survival data have become “the standard way” of 
reporting patient survival in cancer research. Many studies deal with different 
survival times (times to event), particularly when some subjects do not 
remain in the study until its conclusion. With the KM method this might be a 
problem, if men in a PC screening study die from other causes (competing 
even) (219). If the KM method is used to estimate the event-specific survival, 
competing events are censored in the same way as other censored events (i.e., 
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those “lost to follow-up”). For example, men who die from a cause other than 
PC cannot also die from PC.  
When using the KM method, these men would be censored and removed 
from the “at-risk” set. In other words, we assume that these individuals would 
have had the same risk (as those who were not censored). This might lead to 
an overestimation of the probability of dying from PC, especially because 
elderly men with PC often die from other diseases. Many epidemiologists 
prefer to use the competing-risk analysis (219) rather than the KM method 
to correct for such differences. KM rely on the assumption of non-
informative censoring (when time to event and time to censoring are 
independent conditional on the level of covariates). Here, (Paper III), 
competing risk estimates of cumulative incidence were calculated as 
described by Choudhury et al. (220) 
The actuarial life table method is similar to the KM approach but does not 
require exact time of the event. Instead, time is treated as “intervals”. To 
perform this type of calculation we had to have information on the number of 
men at risk (who entered the 1-year time interval), the number of events, and 
the number of men who were censored during the time interval. The life table 
analysis described in Paper III was performed to estimate the observed 
cumulative PC incidence and PC-specific mortality (in the screening and the 
control group) calculated as 1 minus the actuarial survival estimate. 
In Paper III, we wanted to use historical data from 1990–1994 to compare 
the screening and the control group with regard to an estimated PC incidence 
and PC-specific mortality in the absence of PSA screening. During this 
period, which represents the pre-PSA era, PSA was not an established 
screening tool in Sweden. We used what is called Ederer II method (221) to 
assess expected survival rates in a cohort of men from the general population, 
so that the men in our investigation could be considered to be at risk until the 
corresponding men (in the general population) with PC died or was censored. 
Cumulative PC incidence and mortality were estimated as 1 minus the Ederer 
II estimator. To match the age distribution in the screening and the control 
group when calculating the expected estimates, we used 1-year age stratum. 
These calculations were based on the entire male population in Göteborg.  
Cox proportional hazards regression analysis: This model estimates the 
effects of several explanatory covariates (continuous or categorical) on the 
hazard of an event. The hazard can be explained as the instantaneous risk of 
having an event (assuming the man to be event free up to this time). In 
contrast to the survival function, which is focused on not having the event, 
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the hazard function is focused on the event actually occurring. The hazard 
ratio is the ratio of the hazard rates and can also be regarded as a measure 
of how frequently a certain event happens in one group compared to another 
group. The hazard ratio is presumed to be constant over time (the 
“proportional hazard assumption”) and, in two of our investigations (Papers 
II and IV), we used the Cox model and defined the event as PC, GS ≥ 7 
disease, or PC death (Paper IV). In the study reported in Paper IV, it was 
used to explore the relationships between multiple covariates (age, PSA, F/T 
PSA, PSAV, prostate volume, previous biopsy and the presence of voiding 
symptoms). The strength of association was presented as Harrell’s 
concordance index (c-index; discussed below) (222).  
Discrimination and calibration in predictive models 
Risk prediction models are valuable tools for cancer prevention and 
management. When assessing the performance of a risk algorithm, the most 
important component to consider is the ability of the algorithm to distinguish 
between individuals who will and those who will not develop a disease (an 
event), or between those who have the disease and those who do not. This is 
known as “discrimination” and refers to how well the model differentiates 
those at higher risk of having the event/disease from those at lower risk. It 
depends on the distribution of individuals’ characteristics within the 
population in which the model is being applied. The performance of a 
screening test in discriminating affected from unaffected individuals is 
usually evaluated in terms of detection rate – or sensitivity – for a given 
false-positive rate (specificity). The relationship between sensitivity and 
specificity is often illustrated as a plot called a receiver operating 
characteristics (ROC) curve. The area under this curve (AUC) is also referred 
to as concordance (or c) statistic which is commonly used as a summary 
estimate of test performance – or predictive accuracy – in terms of AUC. It 
can take values from 0.5 (not a good test) to 1.0 (the ideal discriminatory 
test). In other words, the c-statistic is a unitless index applied to estimate the 
probability that a randomly selected individual/man who experienced the 
outcome (PC or equivalent) will have a higher probability of having the 
outcome compared with a randomly selected individual/man who did not 
experience it. AUC was not calculated in the present studies. Instead, as 
discussed in Paper II and in Paper IV, we used the c-index proposed by 
Harrell et al. (223, 224), which can be described as a measure of the 
predictive ability of a survival model. In short, this index can be seen as a 
generalization of the AUC for time-to-event data, and, comparable to as for 
ROC curves, c=0.5 stands for “random predictions” and c=1 for “a perfectly 
discriminating model” (222). 
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Discrimination alone is not sufficient to evaluate a model’s predictive 
capability, and hence the model must be calibrated. Calibration or 
“goodness of fit” is a very important property of a model, because it reflects 
the extent to which the model correctly estimates the absolute risk, and 
whether the values that are predicted agree with the observed values (225). A 
calibration plot illustrates the relationship between observed and predictive 
values and shows how closely the risks predicted by a certain model agree 
with the individual’s true risks. Discrimination and calibration are both 
important and should be considered when evaluating the performance of a 
model. Calibration is often underreported in medical studies. In this thesis, 
we have focused on predictive ability of different variables rather than the 
individuals’ risks, hence no calibration has been carried out.  
Characterizing risk predictiveness  
The variation in risk of disease in the population under investigation can be 
illustrated using a graphical tool, called the Lorenz curve. In economics, this 
curve is used for representing inequality in the distribution of wealth. A 
recent paper by Mauguen et al. (226) describes the utility of the Lorenz curve 
in public health research. As outlined in Paper IV, we used a similar curve to 
illustrate the proportion of men that required further examination (Y-axis) 
versus the proportion of men with GS ≥ 7 disease (X-axis). In this analysis, 
we wanted to identify many high-grade cancers but examine only a few men 
after stop age. The optimal model in this context would identify men in the 
lower right corner. 
 
 
 
Figure 13. The 
proportion of men that 
must be further 
examined to identify 
fixed proportions of 
Gleason score ≥ 7 PCs. 
We aim to “detect many 
high-grade cancers, but 
investigate few men”.   
Prostate Cancer Screening: Outcomes and Risk Prediction   
 
 61 
Risk assessment 
When discussing “risk” in epidemiology, the aim is to measure the 
probability of a certain outcome during a specific period of time. In a cohort 
study of cancer, risk ratios and rate ratios are commonly used to compare 
two groups (e.g., a screening and a control group, or attenders and non-
attenders) with regard to the frequency of the disease, and the term “relative 
risk” is often used to encompass both. These measures indicate the “strength 
of association”. A risk ratio is calculated by dividing the cumulative 
incidence in the exposed group (CIe) by the cumulative incidence in the 
unexposed group (CIu): risk ratio = CIe/CIu. 
 PC deaths No PC deaths Total Cumulative incidence 
Screening arm 112 9,837 9,949 112/9,949 = 1.13% 
Control arm 158 9,787 9,945 158/9,945 = 1.59% 
 
Risk ratio = 1.13/1.59 = 0.71. 
In the study reported in Paper III, we found that men in the screening group 
had 0.71 the times the risk of dying of PC compared to men in the control 
group. 
Rate ratios (RRs) are related to risk ratios, but differ in that they represent a 
proportion related to time of exposure. In PC screening, the RR can be 
calculated as the ratio of the incidence rate in a screened group divided by the 
incidence rate (cases per person-years) in a non-screened group (controls). 
The RRs in Paper III were calculated as follows: 
 PC deaths Person years Rate 
Screening arm 112 177,091 112/177,091 
Control arm 158 177,152 158/177,152 
 
The PC mortality was 112/177,091 = 0.63 per 1,000 person-years in the 
screening arm and 158/177,152 = 0.89 per 1000 person-years in the control 
arm, which gives a rate ratio of 0.63/0.89 = 0.71. 
Men in the screening group had 0.71 times the rate of PC deaths compared to 
the men in the control arm. In other words, PC mortality is reduced by  
1–0.71 = 29% for those who underwent screening. In this example, risk ratio 
and rate ratio agree, but this is not always the case. For instance, assume that 
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the same proportion of men would die from PC in both groups. Then the risk 
ratio would equal 1. If, however, the men died earlier in the control arm then 
in the screening arm, then there are fewer person years in the control arm 
compared to in the screening arm. This would lead to a higher rate of PC 
deaths in the control arm and lower rate ratio for screening versus controls. 
Rate ratio reflects the event-free follow-up time for each man and gives a 
better estimate in this type of investigation. However, both rate ratios and risk 
ratios can be used to calculate risk. 
Risk can also be estimated in terms of cumulative risk/incidence, because that 
refers to the occurrence of risk events (e.g., PC diagnosis or PC death). 
Survival analyses are therefore common in randomized controlled studies. 
These methods assess the time it takes for a certain event to occur, called 
“time to event”. An example of an event is PC diagnosis or death, and study 
participants can be followed for various lengths of time. Observations are 
censored if information regarding the participants’ survival time is 
incomplete. For instance, if a man in such a screening study emigrates before 
he experiences the event (PC), he is censored so that his survival time is 
calculated up to the time of emigration, knowing that this man was not 
diagnosed with PC while he was under observation in the screening study. 
Censoring can also be done for drop-outs and men who die from other 
causes, because these individuals are no longer “at risk” of the event studied. 
Censoring is an important issue in survival analyses, and it represents a 
certain type of “missing data”. However, individuals that are censored do 
contribute information on time at risk, even if they have not been diagnosed 
with PC during the observation period. The various types of survival analyses 
that are used are discussed in chapter 3.3. Non-parametric estimations, such 
as the Kaplan-Meier (product-limit) method and the actuarial approach (221) 
are often used in epidemiology and medicine. 
Number needed to screen (NNS) and number needed to treat (NNT): 
NNS can be defined as the number of men that must be screened during a 
given period of time, in order to prevent one PC death (227). This represents 
a measure of the effect of the screening programme. In Paper III, all men in 
the screening arm were included in the calculations (even if they were non-
attendees and did not participate in the programme), and therefore it is more 
correct to describe NNS as “number needed to invite” (NNI).  
NNI is calculated as 1 divided by the absolute risk reduction of the given 
endpoint between the two study arms. In the Göteborg screening trial 10,000 
men were randomized to each arm (screening and control arm, respectively). 
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NNS or NNI = 1 / (158 - 112 PC deaths) per 10,000 men = 217 
NNT is often used in epidemiological studies to describe the effect of an 
intervention or treatment (228). NNT is affected by the follow-up time and 
type of study population, and can therefore be difficult to compare between 
studies. However, many men with screen-detected and low-risk PC are not 
given immediate treatment (some are offered surveillance), NNT represented 
the NND, that is, the number of men that had to be diagnosed to prevent one 
death. We calculated NND as 1 divided by the absolute PC mortality 
reduction multiplied by the excess rate/incidence:  
1528 PC (diagnosed in the SG) - 1124 PC (diagnosed in the CG) = 404 
(excess incidence) per 10,000 men 
NND or NNT = 0.0404 x 217 (NNI) = 9 
3.3.1 Methods and statistical considerations; Paper I–IV 
This section briefly summarizes the materials and methods used in each of 
the four studies underlying this thesis (Papers I–IV). The strengths and 
limitations of the methods applied are also discussed. 
PAPER I 
The aim of the first study was to investigate whether men with PSA  
≥ 3 ng/mL and voiding symptoms were at increased risk of being diagnosed 
with PC (at the time of the actual examination/biopsy). Long-term outcomes 
were not evaluated. All men with a PSA level of ≥ 3.0 ng/mL were offered 
consultation and additional biopsies. Men with PSA below the threshold were 
not further evaluated, but they were invited for assessment again after  
2 years. The study cohort consisted of the men who had an elevated PSA  
(≥ 3.0 ng/mL) at least once during the study period (1995–2010). For men 
who were biopsied on more than two screens, only the first biopsy result was 
included in this analysis. 
In the waiting room, directly before the examination, the attenders completed 
a self-administered study-specific questionnaire. This instrument included 
one question which concerned obstructive voiding symptoms: “Do you have 
voiding symptoms in terms of weak stream or difficulty emptying the 
bladder?” The answers were ranked on an ordinal scale from 1 to 3: 1, no 
symptoms; 2, minor/moderate symptoms; 3, major/severe symptoms. The 
data obtained were dichotomized so that men who answered “2” or “3” were 
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regarded as having voiding symptoms, and those who answered “1” were 
considered asymptomatic. 
 
Statistics 
Logistic regression models are often used to determine the association 
between several explanatory variables and a dichotomous variable (e.g., 
cancer or no cancer). In the present research, multivariable logistic regression 
was performed to assess the impact of the different covariates on biopsy 
outcome at a particular time point (first biopsy).  
Differences between the groups (benign vs. cancer) and (asymptomatic vs. 
symptomatic) were evaluated. The impacts of the covariates age, prostate 
volume, tPSA, F/T PSA ratio, and voiding symptoms were assessed by 
univariate logistic regression analyses, and variables with a statistically 
significant impact were retained in the final multivariable model. Age, tPSA, 
F/T PSA ratio, and prostate volume were used as continuous variables, and 
voiding symptoms were set as a dichotomous variable (symptoms present or 
absent). Odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated for all covariates. The level of statistical significance was set at  
p < 0.05. 
The chi-square test can be used to compare variables for randomly sampled 
data, and to determine whether a significant relationship exists between two 
categorical variables. For example, in the present setting, the chi-square test 
was used for comparison of voiding symptoms in men with benign biopsy 
versus those with PC.  
The nonparametric Mann-Whitney U test is used to analyse the difference 
between medians of different groups. Unlike the t-test, the Mann-Whitney 
method does not require normally distributed data. 
Methodological considerations  
In this study, we had no information on non-attenders (men who were invited 
but did not participate in the screening programme). The data later presented 
in Paper III showed that these men had a higher risk of PC, but offered no 
data on their symptoms and comorbidities. A healthy selection bias can be 
the result of asymptomatic men being more likely to reject invitations to PSA 
screening and prostate examinations. Avery et al. (229) interviewed men 
concerning their decisions regarding PSA testing and found that many men 
felt that a PSA test was unnecessary because they lacked voiding symptoms, 
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thus identifying themselves as being at lower risk of PC and therefore 
declining further investigations.  
No validated questionnaire for assessing voiding symptoms was available for 
use in our investigations. When the Göteborg screening study was planned 
during the early 1990s, the International Prostate Symptom Score (IPSS) 
questionnaire (230) was not being applied in Sweden, whereas today it is 
recommended for all men seeking consultation for urinary problems. If we 
had used IPSS, a better survey could have been made. Furthermore, we had 
no information on symptoms in men with PSA < 3.0 ng/mL, and thus no 
conclusion in this regard can be drawn for men in this PSA range.  
PAPER II  
The second paper reports our study of 5,174 participants in the first round of 
screening (1995–1996), who had an initial PSA level of < 3.0 ng/mL. The 
aim was to evaluate the long-term outcome in these men, but also to assess 
whether the F/T PSA ratio can be useful as a prognostic marker in this PSA 
range. The men were stratified into subgroups according to baseline PSA 
level, and the follow-up time was 19 years. 
Statistics 
Kaplan Meier estimates were used to calculate cumulative incidence, and 
differences between men in the various PSA strata were tested for 
significance by the log rank test (p < 0.05). We assumed that, at any given 
time, men who were censored would have the same prospects as those who 
continued to be followed in the programme. We assumed that PC 
probabilities were the same for men recruited early and late in the study, and 
that the events occurred at the specified time. Harrell’s concordance index 
(222) and the likelihood ratio test were used to determine whether F/T PSA 
ratio added predictive value to tPSA. Models that included age and tPSA 
were compared with models that included age, F/T PSA ratio, and the 
interaction between F/T PSA ratio and tPSA. 
Methodological considerations  
Paper II describes a cross-sectional test result, and the outcomes might not be 
directly transferable to other populations with different age distributions or 
underlying PC prevalence. Chiefly six-core biopsies were performed in the 
Göteborg screening study, whereas 10–12 cores are more common today, and 
MRI-targeted biopsies are also emerging (26). Undersampling of the prostate 
leads to clinically significant cancers being missed on initial biopsy (231), 
and it has been suggested that a repeat biopsy should be performed when 
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using traditional sextant sampling. However, our study has a very long 
follow-up, which enables cancer detection, with repeated screening.  
PAPER III 
This study analysed the main endpoints PC-specific mortality and PC 
incidence according to the intention-to-screen principle: “Once randomised, 
always analysed”. This means that all outcomes were analysed according to 
the group to which the men were randomized, regardless of whether they 
were allocated to the screening group, and did not attended, or to the control 
group, in which they could have been tested outside the programme.  
In this way we “preserved randomization”, because the aim of randomization 
is to equalize prognostic factors. Inasmuch as the men in the control group 
had access to opportunistic PSA testing (mainly during the last 10–15 years), 
the actual difference between the two study arms is more representative of a 
comparison between organized screening and opportunistic PSA testing than 
between screening an no screening. 
Observed versus expected data 
The observed cumulative PC incidence and PC mortality were calculated by 
life-table analysis (in the screening vs. the control group). Follow-up time 
was calculated from start of the study (January 1, 1995) to the date of the 
event (PC diagnosis or PC death). The men who did not experience an event 
were censored at date of emigration, death, or last follow-up (December 31, 
2016).  
Incidence and mortality data from the screening study were also compared 
with expected rates (ERs), by using widely available data from the years 
before PSA testing in Sweden. ERs were calculated based on historical PC 
incidence and mortality data from Statistics Sweden, for the period 1990–
1994. At that time, PSA testing was virtually non-existent in Göteborg. This 
calculation allowed us to extrapolate how the outcomes might have been with 
no PSA testing available to the study population. This type of estimation has 
previously been described by our research team (194). We used 1-year age-
group incidence and mortality rates to reflect the actual distribution of events 
in all men (all ages), who were randomized. To adjust for exclusion of 
prevalent cancers, we subtracted the observed mortality rate for prevalent 
cases from the expected mortality (from the pre-PSA era). Expected 
cumulative mortality and incidence were estimated as 1 minus the Ederer II 
survival estimate (221). The validity of using historical data could be 
considered high, since PC mortality has been fairly constant and the natural 
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history of PC unchanged (during the last 25 years). The observed cumulative 
PC incidence and mortality (for screened men and controls) were calculated 
from start of the study (January, 1, 1995) to the date of the event (PC 
diagnosis or PC death). Those who had no event, were censored at time of 
emigration, death from other causes, or December 31, 2016, whichever 
occurred first. The Greenwood method (232) was used to estimate standard 
errors.  
Comparisons between groups were performed using rates (number of events 
divided by the total number of person-years) but also using cumulative 
incidences calculated by the actuarial life table approach. ERs were estimated 
using historical data (as described above). Competing risk estimates of 
cumulative incidence were calculated as described by Choudhury et al. (220). 
Adjusted rate ratios (RRs) for PC mortality were calculated with correction 
for non-participation (233). 
Secondary endpoints were identifying and analysing subgroups with higher 
PC mortality, formed on the basis of adherence to the programme and the 
time of diagnosis. Three subgroups were identified and defined as listed here: 
• Prevalent cancers: PCs diagnosed at the time of the first 
invitation/screening occasion. 
• Cases detected after the screening period (after stop age). 
• PC in non-attenders (men who were invited but never 
participated in the programme). 
Methodological considerations  
A competing event is defined as any event that prevents the event of interest 
from occurring. For example, if a man dies from a heart attack during the 
study period, he cannot die from the cause of interest (i.e., in our study PC). 
Expected rates (ERs) calculated by the Ederer II and life table methods do not 
consider competing risks (the same as for the KM method), so these censored 
observations (men dying from other causes) are removed from being “at-risk” 
and thereby assuming that these men would have had the same risk of PC 
death as those who were not censored. In other words, such calculations can 
result in overestimations. This is a common problem in clinical research, 
especially because study populations often consist of elderly individuals. 
Koller et al. reviewed 50 clinical studies performed on individuals susceptible 
to competing risks (and published in high-impact journals), and found issues 
affecting competing risks in 70% of all these articles (234). By comparison, 
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the observed cumulative PC mortality reported in Paper III was estimated 
using both life table and competing risk methodology.  
Even if as many as 20,000 men were randomized in the Göteborg screening 
trial, it was not as large as the PLCO trial or the whole ERSPC. On the other 
hand, this is compensated for by the long follow-up and the large number of 
events (270 PC deaths). In the PLCO study the corresponding number of PC 
deaths was 303 cases (235). 
PAPER IV 
The study cohort described in this paper was based on men who were 
attenders and left the Göteborg screening trial with no previous PC diagnosis. 
Those who were younger than 67 years at their final screen were not included 
in the analysis, because men who left the trial before the age of 67 were 
actually invited to one or more screens, that they did not attend (even if they 
were “attenders” on at least one occasion). Thus choosing not to participate in 
the final screening rounds was considered to be a different issue.  
Men in the cohort were stratified by their PSA level at the time of their final 
screen. Men with PSA < 3 ng/mL and no biopsy; men with PSA ≥3 ng/mL 
and no biopsy (due to comorbidities or refusal); men with PSA ≥ 3 and a 
benign last biopsy, and men with PSA < 3 ng/mL and a benign biopsy at last 
screen. The fourth of these groups consisted of those who were biopsied 
secondarily to the MRI pilot study (in which 1.8 ng/mL was used as a cut-
off) (236). The first consort diagram was constructed as shown on the next 
page (Figure 14). 
The main end-point was GS ≥ 7 PC during follow-up (after final termination 
of screening). The four subgroups were reduced to two main groups 
(designated A and B), because men with PSA ≥ 3 ng/mL and no biopsy and 
men with PSA < 3 ng/mL and a benign biopsy, could be regarded as deviant 
from the protocol. 
For men in group A, our aim was to evaluate whether the covariates age, 
tPSA, F/T PSA ratio, PSAV, and/or previous biopsy could predict risk of  
GS ≥7 disease after the end of the study. For men in group B, we also had 
information on prostate volume and voiding symptoms, because these 
individuals underwent urological evaluation at their final screen (same as for 
men with PSA ≥3 ng/mL at first screen, in Paper I). We evaluated whether a 
model including one or several covariates could add predictive value to PSA, 
when identifying those who could benefit from continued screening.   
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Figure 14. Initial flow-chart of study cohort in Paper IV. 
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Statistics 
Cumulative PC and GS ≥ 7 incidence were analysed as 1 minus the KM 
estimates. Follow-up time was calculated as time from the date of last PSA in 
the screening trial to the date of diagnosis or censoring (date of emigration or 
death, or December 31, 2016). The covariates mentioned above was 
examined by comparing increasingly larger Cox regression models. Variables 
were added one at a time in the order of increasing univariable c-indices. The 
predictive ability was measured using Harrell’s c-index, and the models were 
compared using the likelihood ratio test. 
PSA velocity (PSAV) was calculated as the slope in a linear regression model 
based on all available PSA measurements for each man. Log-transformed 
PSA values were used. Relative long-term PSAV (percent per year) was also 
calculated. In addition to velocity based on tPSA we examined velocity of 
F/T PSA, and we used restricted cubic splines to investigate potential non-
linear relationships. Neither F/T PSA velocity nor non-linearity improved the 
models, and hence these results were not reported in the paper.  
It was also our intention to use one or more covariates to identify a subgroup 
of men who would benefit from continued screening and estimate how many 
of the men in the cohort (i.e. the size of this subgroup) would benefit from 
continued screening after stop age. This was illustrated by plotting a curve, 
similar to a Lorenz curve (described in statistical methods, page 60). 
Methodological considerations  
The median follow-up period was 8.6 years (after the final screen in the 
study), and the median age at last follow-up was 80.2 years. As the estimated 
age at time of PC death is 82 years (in Sweden), we are expecting additional 
PCs and PC deaths with longer follow-up. It is therefore too early to evaluate 
the “true” PC-specific mortality in this study population. So far, 21 men had 
died from PC. This number will be higher with a longer follow-up period. 
Another limitation in this paper is that some men (n = 43) only had two PSA 
values within the study. Outlying values due to short-term variation of PSA 
could bias these estimates. PSAV is a measurement of how fast PSA levels 
increase over a time period. Some recommendations for the use of PSAV 
include collection of multiple PSA values (over a period no less than 24 
months) and a minimum of three values.  
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4 RESULTS AND COMMENTS 
PAPER I 
Of the 7,625 men who attended the screening study, 34% (n = 2,590) had a 
PSA level of ≥ 3 ng/mL on at least one screening occasion (1995–2010). The 
majority of these men (n = 2,353) answered the questionnaire and accepted 
TRUS and prostate biopsy. The median prostate volume was 37.8 cm3 
(interquartile range (IQR) 30.0–48.6). Men with a benign biopsy (n = 1,720) 
had larger prostates and reported voiding symptoms more often than men 
with PC (50% vs. 40%; p < 0.001). A total of 633 PCs were detected. 
 Benign, n = 1,720 PC, n = 633 
Median age (IQR) 63.0 (59.8–65.8) 64.3 (60.8–66.8) 
Median volume cm3 (IQR) 40.0 (31.6–50.8) 32.6 (26.6–41.6) 
F/T PSA ratio in % (IQR) 20.6 (15.7–26.5) 16.8 (12.0–23.3) 
tPSA in ng/mL (IQR) 3.8 (3.3–4.6) 4.1 (3.4–5.6) 
Voiding symptoms (%) 867 (50%) 255 (40%) 
 
Table 6. Clinical characteristics of the subjects. Benign vs. prostate cancer at time for the first 
prostate biopsy. 
In the multivariable logistic regression, age and PSA level were significant 
predictors of PC detection, whereas prostate volume, F/T PSA, and voiding 
symptoms were correlated with a lower odds of PC detection: 
 Odds ratio (OR) 95% CI P value 
Age at time of biopsy 1.10 1.07–1.12 < 0.001 
Prostate volume (cm3) 0.96 0.96–0.97 < 0.001 
F/T PSA ratio in % 0.97 0.96–0.99 < 0.001 
tPSA in ng/mL 1.09 1.06–1.12 < 0.001 
Voiding symptoms 0.78 0.63–0.98 0.032 
 
Table 7. Multivariable analysis of the impact of different covariates on biopsy outcome in men 
with a tPSA level of ≥ 3 ng/mL. 
In this study 378 PCs (31%) were detected in 1,230 asymptomatic men, and 
255 PCs (23%) were detected in men who reported voiding symptoms  
(n = 1,123). When the incidence of an outcome is low (< 10%), the adjusted 
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odds ratio (OR) derived from the logistic regression is similar to the risk ratio 
(237). Incidence of the outcome in this analysis was > 10%, and based on our 
data, the risk ratio was 0.84 (this was not reported in the Paper I).  
PAPER II 
This study evaluated long-term outcome in men with a baseline PSA below  
3 ng/mL (n = 5,174). F/T PSA ratio was also assed as a prognostic reflex test 
in this PSA range. 
The median age at initial screening round was 57.2 years (IQR 53.8–61.4). 
During a median follow-up of 18.9 years (IQR 18.1–19.3), 754 PCs were 
diagnosed, which corresponds to a cumulative incidence of 17.2%. Median 
age at time of diagnosis was 66.8 years (63.7–69.1). In total, 224 cases (30%) 
were GS ≥ 7 cancers, and 108 out of these 224 (48%) were non-screen 
detected and diagnosed after the men terminated the screening programme 
(after stop age, 67–71 years).  
Figure 15. Cumulative prostate cancer incidence in men with an initial PSA < 3ng/mL. 
At baseline, 57% (n = 2,931) of the men had PSA levels of ≥ 0.99 ng/mL. 
Among them, the cumulative risk at 20 years was 7.9%, and the cumulative 
risk for GS ≥ 7 cancer was 3.7%. Seven men died of PC (five of them were 
diagnosed after stop age).  
About one third of the men (n = 1,708) in this cohort had a PSA level 
between 1 and 1.99 ng/mL at initial screen. The cumulative PC risk at 20 
years was 26.0% (9.7 % for GS ≥ 7 cancers). Fifteen men later died of PC 
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(ten of them after stop age). For the remaining 535 men (10%) with  
PSA 2–2.99 ng/mL, the cumulative risk was 40.3% (10.9% for GS ≥ 7 PC), 
and three out of six PC deaths were diagnosed after stop age. Of the total 
study population, 74% represented complete attenders (e.g., the invitation 
lead to a PSA screen). 
In all, 28 men died of PC, which corresponds to a cumulative risk of 0.7% 
(95% CI: 0.5–1.0). Most of these cases (n=18) were diagnosed after stop age.  
Free-to-total PSA  
Adding F/T PSA did not improve PC prediction as assessed by Harrell’s  
c-index (base model 0.76 vs. 0.76), or considering the likelihood of the model 
(p = 0.371). The corresponding figures for men with GS ≥ 7 disease, were 
0.68 vs. 0.67 and p = 0.079. 
 
Figure 16. Scatter plot of F/T PSA vs. PSA at baseline. Blue indicates men who are later 
diagnosed with PC, and red stands for men who died of PC. Most of the men had PSA levels of 
< 1.0 ng/mL at first screen. 
The scatter plot above illustrates distribution of the men in the study 
population with regard to PSA level and F/T PSA ratio. Among the 28 men 
who later died of PC (red in the plot), 17 had F/T PSA below and 11 F/T PSA 
above the median PSA. Adding F/T PSA did not provide more accurate 
prediction of which men who would develop PC or die from the disease.  
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PAPER III 
This paper describes the main study presented in this thesis, and it was 
performed to compare the screening group and the control group with regard 
to PC mortality and incidence. We also compared the findings of these 
assessments with expected incidence and mortality rates based on historical 
(pre-PSA) data. 
Follow-up time was calculated up to December 31, 2016. The final invitation 
to the screening study was sent in 2014, and the attendance rate at 22 years 
was high (77%). Of the 7,635 men who attended the screening programme, 
2,672 (35%) men had an elevated PSA (≥ 3 ng/ml) at least once, and 2,525 
(33 %) men underwent at least one prostate biopsy. This resulted in 1,046 
cancers being diagnosed within the screening trial (screen-detected PCs). An 
additional 482 cancers were diagnosed in men in the screening arm, albeit 
outside the programme (non-screen-detected PCs). Thus, a total of 1,528 men 
randomized to screening were diagnosed with PC. The corresponding number 
of PCs diagnosed in the control group was 1,124. 
Cumulative PC incidence at 22 years was 18.7% (95% CI 17.9–19.6) in the 
screening group and 14.4% (95% CI; 13.6–15.2) in the control group. This 
can be compared with an expected rate of 10.3%, according to data from the 
pre-PSA era. Expected rates (ERs) were similar to PC incidence found in 
non-attenders.  
 
Figure 17. Observed and expected PC incidence up to December 31, 2016. Expected values 
are based on PC incidence in Göteborg 1990–1994 (the pre-PSA era) and extrapolated to data 
from the screening study.   
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 CONTROL ARM SCREENING ARM 
 
  
Prevalent 
cancers 
 
PCs detected 
during  
round 2-10 
 
PCs detected  
after stop age 
 
PCs detected in  
non-attenders 
 
      
Number of PCs 1,124 144 1,023 213 148 
Number of PC deaths 158 (14%) 15 (10%) 24 (2%) 26 (12%) 47 (32%) 
Md age at diagnosis 68.8 (64.8–72.9) 60.5 (57.4–63.7) 65.8 (62.6–67.7) 76.1 (73.2–78.8) 68.8 (64.1–73.7) 
Md PSA at diagnosis 8.6 (5.1–19.0) 6.2 (4.0–11.2) 4.3 (3.5–6.0) 10.0 (6.3–22.5) 19.0 (7.6–61.0) 
Clinical stage      
 T1 545 (48%) 86 (60%) 805 (79%) 95 (45%) 46 (31%) 
 T2 377 (34%) 48 (33%) 187 (18%) 64 (30%) 48 (32%) 
 T3/T4 155 (14%) 10 (7%) 22 (2%) 46 (22%) 49 (33%) 
 Tx 38 (3%) – 9 (1%) 8 (4%) 5 (3%) 
 Unknown 9 (1%) – – – – 
Gleason score      
 ≤ 6 494 (44%) 110 (76%) 815 (80%) 63 (30%) 43 (29%) 
 7 407 (36%) 22 (15%) 176 (17%) 92 (43%) 44 (30%) 
 ≥ 8 186 (17%) 12 (8%) 32 (3%) 57 (27%) 47 (32%) 
 Unknown 37 (3%) – – 1 (0.5%) 14 (9%) 
Risk group      
 Low 269 (24%) 62 (43%) 616 (60%) 28 (13%) 17 (11%) 
 Intermediate 434 (39%) 59 (41%) 326 (32%) 88 (41%) 37 (25%) 
 High 207 (18%) 19 (13%) 55 (5%) 57 (27%) 43 (29%) 
 Advanced 136 (12%) 4 (3%) 16 (2%) 28 (13%) 41 (28%) 
 Unknown 69 (6%) – 10 (1%) 12 (6%) 10 (7%) 
Lymph node MET (N1) 25 (2%) 3 (2%) 7 (1%) 2 (1%) 8 (5%) 
Distant MET (M1) 101 (9%) – 8 (1%) 26 (12%) 32 (22%) 
      
      
Treatment      
Prostatectomy 329 (30%) 66 (46%) 428 (42%) 24 (11%) 31 (21%) 
Radiation therapy 118 (11%) 17 (12%) 68 (7%) 15 (7%) 18 (12%) 
Surveillance 388 (35%) 52 (36%) 493 (48%) 89 (42%) 28 (19%) 
Endocrine treatment 268 (24%) 7 (5%) 26 (3%) 82 (38%) 69 (47%) 
Unknown 11 (1%) 2 (1%) 8 (1%) 3 (1%) 2 (1%) 
      
 
Table 8. Descriptive statistics of PCs detected in the control arm vs. the subgroups in the 
screening arm of the Göteborg Randomized Population-Based PC Screening Trial. Last 
follow-up was December 31, 2016.  
The table presented above outlines the tumour features and treatments in 
different groups. In general, most of the cancers detected in the screening 
group were early-stage disease. Considering PSA at the time of diagnosis and 
number of men with advanced disease, the levels observed in the screening 
arm (5.1 ng/mL and 89/1,528 PCs [6%]) were lower than those noted in the 
control arm (8.6 ng/mL and 136/1,124 PCs [12%]). This is also reflected by 
the treatments given: endocrine therapy was recommended for 12% of men 
with PC in the screening group and 24% of the men in the control group. 
  Maria Frånlund 
 76 
However, treatments with curative intent were similar in the two study arms: 
447/1,124 (40%) vs. 667/1,528 (44%). 
Non-attenders in the screening arm and men in the control arm were 
diagnosed with PC at the age of approximately 69 years, whereas attenders 
(diagnosed in round 2–10) were about 66 years. Non-attenders had more 
advanced cancers at diagnosis, and 69/148 (47%) of them received endocrine 
therapy.  
 
Figure 18. Observed and expected PC mortality up to December 31, 2016. Expected values 
are based on PC mortality in Göteborg 1990–1994 (the pre-PSA era) minus PC mortality due 
to prevalent cancers.  
There was no discrepancy in all-cause mortality between the screening and 
the control group (RR 1.02, CI 0.97–1.07). However, the number of PC-
specific deaths was higher in the control group: 158 vs. 112, corresponding to 
a RR of 0.71 (95% CI 0.56–0.90). The cumulative risk of dying from PC at 
22 years in the trial was 1.59% (95% CI 1.32–1.90) in the screening arm 
compared with 2.17% (95% CI 1.86–2.54) in the control arm; the estimated 
rate for the pre-PSA era corresponded to 3.01%. As noted for the incidence 
curve, expected values for PC mortality were similar to the mortality rates for 
non-attenders.  
At 22 years in the trial, the NNI to prevent one PC death was 217 and the 
NND was 9. The corresponding rates at earlier time points (as reported in 
previous publications) were, respectively, 293 and 13 at 14 years, and 243 
and 11 at 18 years. 
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Three groups of men with PC who were at higher risk of death due to this 
disease were identified in Paper III: 
• Men who were diagnosed at first screen (prevalent PCs) 
• Men who were diagnosed after stop age 
• Men who were non-attenders  
Among the 144 men who had a PC detected at first screen, 15 (10%) men 
later died of PC. Eleven of these 15 men were diagnosed with GS ≥ 7 disease, 
and nine were aged ≥ 60 years at the time they were invited to participate in 
the study. Men who died of PC in this group had, at time for diagnosis, a 
median PSA level of 10.7 ng/mL (IQR 6.2–28.7), and F/T PSA was 10.6% 
(IQR 6.1–13.2). Median age at the time of PC death in these 15 men was 71.8 
years (IQR 70.0–72.9).  
A total of 213 men were diagnosed with PC after stop age (67–71 years), 
and 26 of those subjects (12%) later died of PC. The median age at time of 
diagnosis for these 26 men was 78.2 years (IQR 73.1–81.6), and age at time 
of death was 80.4 years (IQR 76.6–82.9). Twenty-five of the 26 men had  
GS ≥ 7 disease. 
Most deaths (47 of 148 cases) occurred in the group designated PCs in non-
attenders, which consisted of men who were invited to screening but did not 
participate (n = 2,310). The cumulative risk of PC death at 22 years was 
much higher for the non-attenders than for the attenders (4.1% vs. 1.1%). 
 Rate ratios for non-
attenders vs. attenders 
Non-attenders vs. men in 
the control group 
PC incidence   
Rate ratio: 0.45 (95% CI: 0.38–0.53) 0.71 (95% CI: 0.60–0.84) 
PC mortality   
Rate ratio: 3.23 (95% CI: 2.22–4.70 1.63 (95% CI: 1.18–2.25 
All-cause mortality   
Rate ratio: 2.34 (95% CI: 2.19–2.50) 1.92 (95% CI: 1.80–2.04) 
 
Table 9. Rate ratios in non-attenders vs. attenders and vs. controls. 
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Figure 19. Consort diagram showing the number of PCs, and PC deaths. 
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PAPER IV 
In this study, we investigated the outcomes in men who participated in the 
Göteborg screening trial and had their final screen at stop age (67–71 years). 
These men were free of PC at last screen and had a median of five (IQR 3–7) 
screens during the trial.  
In this study population, most men (n = 3,756) left the screening trail with a 
PSA level of < 3 ng/mL and were therefore not recommended prostate biopsy 
at the time of the final screen. The majority of these men (n = 3,492, 
designated group A) had never been biopsied at previous screens. During a 
median follow-up of 8.6 years (IQR; 5.2–11.7), 124 of the men in group A 
(3.3%), were diagnosed with PC, and 88 (2.3%) of those cases were GS ≥ 7 
cancers. Group B consisted of the men who had an elevated PSA (≥ 3 ng/mL) 
and a benign/negative biopsy (n = 708); 62 (8.8%) of those subjects were 
later diagnosed with PC, and 32 (4.5%) of those cases were GS ≥ 7 disease.  
All men were stratified by PSA level, and cumulative risk of high-grade  
(GS ≥ 7) PC was estimated by the KM method. At 15 years of follow-up, 
men with PSA < 1 ng/mL were found to be at very low risk (~2%), whereas 
men with PSA ≥ 10 ng/mL were at high risk (~20%). Those with PSA  
2–3 ng/mL were at higher risk compared with the men with PSA in the range 
of 3–10 ng/mL, who had been biopsied at the final screen (~13% vs. ~8%). 
Figure 20. Cumulative risk of Gleason score ≥ 7 PCs within 15 years of follow-up after final 
PSA test in the screening trial. 
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A total of 21 men died of PC during the follow-up period (median 8.6 years). 
At 15 years, the cumulative risk of PC death was highest in men with PSA  
≥ 10 ng/mL. The number of PC deaths in each PSA stratum varied between 
two and seven cases. 
Men in the ranges 1–1.99 ng/mL and 2–2.99 ng/mL had a 1.5–2% risk of PC 
death within 15 years. This can be compared to 2.1% for the whole control 
group, at 22 years (results in paper III).  
The predictive accuracy of the Cox regression model for men in group A; 
tPSA had a c-index of 0.77 for GS ≥7 cancers. The predictors were evaluated 
one-by-one and cumulatively (as shown below). Compared with tPSA, none 
of the other variables added predictive value to PSA. 
Group A: PC (GS ≥ 7) in men with PSA < 3 ng/mL at final screen 
  
c-index c-index cum. LR-test 
tPSA 0.77 0.77 0.000 
PSA velocity 0.67 0.78 0.067 
F/T PSA ratio 0.66 0.78 0.217 
Age at final PSA 0.50 0.77 0.727 
Previous biopsy 0.50 0.77 0.463 
 
Table 10. Concordance index for different covariates (Group A). 3554 men had values for all 
variables and these men were included in calculation of the models. 
For men in group B, PSAV had the strongest predictive value: 
Group B: PC (GS ≥ 7) in men with PSA ≥ 3 ng/mL at final screen 
  
c-index c-index cum LR-test 
PSA velocity 0.70 0.70 0.011 
Prostate volume 0.66 0.71 0.051 
F/T PSA ratio 0.63 0.69 0.095 
tPSA 0.55 0.71 0.073 
Voiding symptoms 0.53 0.69 0.517 
Age at final PSA 0.53 0.69 0.368 
Previous biopsy 0.49 0.69 0.412 
 
Table 11. Concordance index for different covariates (Group B). 651 men had values for all 
variables and these men were included in calculation of the models. 
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The other variables did not add predictive value to PSAV in the PSA range  
≥ 3 ng/ml. A low predictive value of tPSA (c-index 0.58) has also been 
shown in the STHLM3 population (144). One explanation could be that men 
with elevated PSA had been previously biopsied at one or several occasions, 
and thus leaving a selected population where the predictive value of tPSA has 
declined. 
 
Table 12. Detection rates at different PSA cut-offs. 
We also performed an assessment to estimate the proportion of men in this 
age group who require additional follow-up to increase the possibility of 
detecting and preventing ~80% of high-grade cancers and PC deaths.  
Most men (n = 2,482) had a PSA level of < 1.6 ng/mL at final screen. 
Subjects with PSA below this level were considered to be of “low-risk” of 
future GS ≥ 7 disease, whereas “only” 24 out of 120 GS ≥ 7 cancers and 5 
out of 21 PC deaths were detected during the follow-up period. To determine 
the proportion of all men that would need to be investigated further we 
evaluated different PSA cut-offs to describe the distribution of later cancers 
being detected. This was also illustrated by the Lorenz-curve (illustrated on 
page 60, in Statistical Methods).  
Among the 44% of the men in the cohort with a PSA level ≥ 1.6 ng/ml at 
time for final screen, 80% of all GS ≥ 7 cancers were detected and 76% of all 
PC deaths were in men above this cut-off. These results indicate that only 
men above this PSA level need continued screening. However, we require 
better tools for selecting these subjects, and the usefulness of PSAV needs to 
be explored more closely. 
All men in the cohort 
PSA cut-offs* 
No. of men in cohort 
n = 4,464 
No. of PCs  
n = 186 
No. of GS ≥7 PC 
n = 120 
No. of PC deaths 
n = 21 
PSA ≥ 1.0 ng/mL 2,985 (67%) 176 (95%) 112 (93%) 18 (86%) 
PSA ≥ 1.2 ng/mL 2,627 (59%) 167 (90%) 106 (88%) 17 (81%) 
PSA ≥ 1.4 ng/mL 2,294 (51%) 161 (87%) 104 (87%) 17 (81%) 
PSA ≥ 1.6 ng/mL 1,982 (44%) 152 (82%) 96 (80%) 16 (76%) 
PSA ≥ 1.8 ng/mL 1,700 (38%) 142 (76%) 88 (73%) 11 (52%) 
PSA ≥ 2.0 ng/mL 1,493 (33%) 133 (72%) 80 (67%) 11 (52%) 
PSA ≥ 2.2 ng/mL 1,278 (29%) 121 (65%) 72 (60%) 11 (52%) 
PSA ≥ 2.4 ng/mL 1,098 (25%) 106 (57%) 59 (49%) 9 (43%) 
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5 DISCUSSION 
Widespread PSA testing has had a marked impact on the epidemiology of 
PC. The incidence of this disease in Sweden has increased considerably, 
mainly among men in midlife. However, patients, doctors, and even guideline 
groups find it difficult to know whether screening should be performed, and, 
if so, how it should be done. PC screening is multifaceted, and there is an 
urgent need for improved screening strategies. The research leading to this 
thesis has analysed and discussed outcomes and predictive factors with the 
aim of improving our understanding of PSA-based screening for PC. 
5.1 RISK ASSESSMENT BASED ON  
URINARY SYMPTOMS 
More than 50% of all men over 50 years of age report problems with 
urinating (238), which is why many men seek medical consultation and 
advice regarding additional PSA testing. Data compiled by the NPCR have 
shown that approximately one third of men diagnosed with PC had their 
urological work-up initiated due to symptoms from the lower urinary tract.  
In the first of the present studies (Paper I), we asked men with elevated PSA 
levels (> 3 ng/mL) about their symptoms, and we found that the absence of 
voiding symptoms was an independent risk factor for PC. However, this 
observation can only be applied to men with elevated PSA levels, and hence 
the true association is unknown. In an investigation of the the HUNT 2 cohort 
in Norway (239), PC incidence and PC mortality were recorded during 9 
years of follow-up, whereas the biopsies in our initial study were performed 
in close connection with completion of the questionnaire in the waiting room. 
That is, we did not analyse long-time data. In 2013, a population-based 
cohort study in the United States (240) found that men treated for lower 
urinary tract symptoms (LUTS) were more likely to undergo a prostate 
biopsy, and this increased diagnostic activity among symptomatic men had 
an impact on how they were selected for further investigations. 
Notwithstanding, a man who complains of increased frequency of urination 
or a poor stream and has a PSA level of > 3 ng/mL is not at higher risk of 
being diagnosed with PC than a man who has a PSA of > 3 ng/mL and no 
apparent bothers. Patients need to be informed that voiding symptoms are 
often due to benign conditions, and urological work-up should follow the 
same routine in these men. Importantly, our findings do not imply that men 
with symptoms should be withdrawn from investigation or PSA testing.  
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Today, there is insufficient evidence to recommend PSA testing in men who 
have voiding symptoms but no other risk factors. We concluded that men 
with symptoms are less likely to be diagnosed with PC if their PSA level is  
≥ 3 ng/mL. This is an important finding, because it contradicts the common 
belief that urinary symptoms are signs of PC, and thus indicates that all men 
should receive advice based on the same guidelines (symptoms or no 
symptoms). Furthermore, prostate volume is highly relevant when evaluating 
PC risk.  
Future research could, for example, be designed as an interventional study 
aimed at determining whether men with urinary complaints are 
overdiagnosed with PC. It appears that gaining such knowledge can be 
useful, because it can help us avoid unnecessary and untimely PSA testing in 
elderly men who are not amenable to treatment of PC with curative intent. 
Such information might also make it possible to circumvent diagnosis of 
clinically insignificant cancers.  
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5.2 RISK ASSESSMENT IN MEN WITH PSA  
< 3 NG/ML AT INITIAL SCREENING 
The aim of a PC screening program is to detect potentially lethal disease, so 
that curative treatment can be offered before the cancer is too advanced. The 
optimal cut-off value for further diagnostics (i.e., biopsy or MRI) is a matter 
of debate, and in 2004 Thompson et al. (140), reported having demonstrated 
that there is no lower PSA limit at which PC cannot be found.  
The results reported in Paper II are based on a rather large cohort of men 
who participated in a long-term screening programme with a high attendance 
rate and few men were lost to follow-up. We evaluated the outcome in men 
with an initial (at first screen) PSA of < 3 ng/mL, because this level is 
commonly used as a threshold for recommending prostate biopsy. Most of 
the PCs detected were low grade (GS < 7), and thus the benefit of detection 
could be questioned. We did not assess any negative impact on quality of life 
(caused by treatments or PC-induced anxiety). 
We found that the baseline PSA level was strongly predictive of the future 
risk of being diagnosed with PC and also the risk of dying from this disease. 
Few men with a baseline PSA level below 1.0 ng/mL later died of PC 
(cumulative risk of 0.3%). These findings are consistent with several other 
reports (207, 241, 242). However, it is clear that, even with biannual PSA 
testing, some cancers are missed. Our analysis showed that in the PSA range 
of 1–3 ng/mL, the cumulative risk of GS ≥ 7 disease was ~10% at 20 years, 
and as many as 28 men in the study population died of PC. This is an 
important finding suggesting that the current screening algorithm has pitfalls. 
Interestingly, approximately half of all GS ≥ 7 PCs (108/224) were not 
detected by screening (i.e., were interval cancers or PCs diagnosed after stop 
age). 
It has been proposed that use of a baseline PSA and a risk-adjusted PSA 
testing strategy might minimize the effect of overdetection (205). A study 
conducted in the United States (242) found that men with an initial PSA of  
< 1 ng/mL had a 10-year PC risk of ~3%, and it was suggested that men with 
this PSA level could safely be re-tested every 10 years. Such an approach 
could reduce both the cost of screening and the overdetection of indolent 
PCs, but still detect tumours that can be treated to lower PC mortality. 
Retesting intervals were not considered in Paper II, but it does seem rational 
to apply a restrained approach in men with PSA levels of < 1 ng/mL. 
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Extrapolation from our data indicates that the risk of GS ≥ 7 disease is very 
low the first 8–10 years of screening (in men with PSA <1 ng/mL), which 
supports the conclusions drawn in the cited study.   
5.2.1 Risk assessment with F/T PSA ratio 
The second of the present investigations (Paper II) also tested the value of 
adding F/T PSA ratio to a predictive model. Several other studies have 
demonstrated that such an approach can be a useful (adding F/T PSA as a 
reflex test to tPSA) in the PSA range 2–10 ng/mL (243-245). The Finnish 
arm of the ERSPC has reported results showing that a low F/T PSA was of 
prognostic value even in men with a baseline PSA of < 3 ng/mL (246), 
although this observation could not be confirmed by our data. In the Finnish 
study, men with a PSA of ≥ 4 or 3–3.99 ng/mL and a F/T PSA of < 16% were 
selected for biopsy. The cumulative risk of PC associated with F/T PSA was 
analysed in quartiles based on the distribution in men with PC. The adjusted 
relative risk for those in the lowest quartile (F/T PSA< 14.2%) was 6.9 
compared with those in the highest quartile (F/T PSA > 23.7%), and thus it 
was concluded that a low F/T PSA is a strong predictor of PC diagnosis in 
men with low tPSA. Considering that the screening algorithm in the Finnish 
study called for biopsy at a low F/T PSA, a higher cumulative incidence of 
PC could be expected for the men identified in this manner. Many men with 
PSA < 3 ng/mL in the first screening round in the Finnish analysis had an 
elevated PSA in the second screening round (4 years later); the authors 
received comments from other researchers regarding this potential bias (247), 
and, after exclusion of these PC cases, the impact of F/T PSA was not 
significantly altered. 
It seems that F/T PSA offers advantages primarily to men with elevated PSA. 
It appears that this ratio is more useful when applied in the PSA range of  
4–10 ng/mL, a strategy that can reduce the number of unnecessary biopsies 
while retaining a high PC detection rate (248). At a PSA level of  
< 1.0 ng/mL, the free PSA is close to its detection limit. Furthermore, the test 
results provided by assays from different manufacturers can vary by as much 
as ~10% (249). Such calibration issues might lead to over-or underestimation 
of the true diagnostic performance, and this aspect must be taken into 
consideration when comparing the results of different studies. In any case, we 
can conclude that the use of F/T PSA ratio should not be recommended for 
men in low PSA ranges. 
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5.3 EFFICACY OF THE SCREENING 
ALGORITHM: OUTCOMES AFTER  
22 YEARS 
Paper III presents the results of the longest follow-up to date in a PSA-based 
screening study. During the last decade, PC incidence in the control arm has 
slowly been approaching the level in the screening arm. At 22 years, a 36% 
excess incidence remains in the screening arm (1,528/9,945 vs. 1,124/9,949), 
although the incidence curves have become more parallel. The absolute 
reduction in PC mortality is still increasing to some extent, while the relative 
risk is decreasing with longer duration of follow-up and a larger number of 
PC deaths. These observations demonstrate that differences in both incidence 
and mortality between the two arms are stabilizing. The RR for PC mortality 
is now 0.71 (95% CI 0.56–0.90). The NNI for screening to prevent one PC 
death was improved, from 243 at 18 years compared to 217 at 22 years, and 
the NND dropped from 11 at 18 years to 9 at 22 years. Our data confirm that 
an organized screening programme reduces mortality by ~30%, a level that is 
similar to evidence from the ERSPC and the PLCO trial (showing a 25–32% 
lower risk) (175).  
5.3.1 Improving prostate cancer screening 
It is clear that screening reduces PC-specific mortality, but how should a 
screening programme be designed to optimize such benefits and at the same 
time reduce the harms of overdiagnosis? This is a complex question, and it is 
necessary to start by identifying the pitfalls associated with the current 
strategy, because there are some protocol-related issues that need to be 
considered. 
When screening starts too late. In the study reported in Paper III, 144 men 
were diagnosed with a prevalent PC (at the initial screening round), and 15 of 
them later died from this disease. Most of these men (n = 80) were over 60 
years of age when they had their first PSA screen. Men diagnosed in 
screening rounds 2–10 had more favourable prognostic features. Similarly, 
the Dutch section of the ERSPC (250), found that men in the second round 
were at 2.9-fold lower risk of dying from the disease, compared with those 
diagnosed in the first round). Initiating screening at ages older than 60 years 
is apparently too late for many men, possibly because the window of cure 
might be missed and numerous men will already have aggressive high-grade 
cancers at the time of diagnosis. Earlier publications have proposed that 
screening should be initiated for men between the ages of 50 and 54 years 
(251), a strategy that would reduce the number of PC deaths and also lead to 
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fewer cases of metastatic disease. One concern with that approach is the risk 
of overdiagnosis when PSA testing is started in midlife. A previous study by 
our group found no difference in PC incidence at termination of screening, 
regardless of whether start age was 50, 55, or 60 years (170). In that study, 
the cumulative risk of PC was ~7%, at age 60, ~14% at age 65, and ~22% at 
age 70, irrespective of start age. These findings indicate that the rate of 
overdiagnosis is not correlated with the age at which screening is initiated.  
Recommendations for screening younger men differ among guideline groups. 
One strategy has been to offer screening to men at high risk, as an individual 
option, starting at 50–55 years of age. The AUA guidelines suggests that 
screening can be considered at an earlier age for men who are younger than 
55 years and have a positive family history or are of African descent (116). In 
the Swedish national guidelines for PC care, men at higher risk are defined as 
those from families with hereditary PC (i.e., men who are BRCA2 positive or 
have at least two close relatives diagnosed with PC at age < 75 years). 
Others, have suggested that a baseline PSA at ages 45–49 years can provide 
risk stratification superior to that based on race or family history (252).  
When screening is terminated too early. Overdiagnosis increases with age 
(253), and older age and comorbidities should always be considered before 
PSA testing. The study outlined in Paper II, showed that 28 men died of PC 
despite screening, and most of these cancers (n = 18) were detected after stop 
age (post screening). It seems rational to assume that some of these deaths 
could have been avoided if PSA testing had continued after the age of 70 
years, or if additional diagnostics had been offered to selected individuals. In 
our subsequent investigation (Paper III), we mapped all cancers in the 
screening group, which revealed that 213 men were diagnosed after stop age, 
and 26 of these men died of PC. The majority of these deaths (20 of 26) 
occurred in men who started screening when they were aged 60 years or 
older. Most men had a PSA level of < 3 ng/mL when they left the study, and, 
although they were approximately 80 years old when they died of PC, some 
of them might have been “saved” if the cancer had been detected in the PSA 
range of 2–3 ng/mL. This observation concurs with reports showing that 
elderly men are more likely to develop high-grade cancers and/or die of PC 
(254, 255).  
The data in Paper III also showed that the stage distribution of cancers 
detected after stop age was shifted towards more advanced PC (only 13% 
were low-risk PC). It has been suggested that in Sweden it is less likely that 
curative treatment will be given to men who are in their seventies and have 
non-metastatic high-risk PC but are otherwise healthy, than to younger men 
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with the same life expectancy (256). A possible explanation for this 
difference is that physicians underestimate the life expectancy of many 
elderly men. The Göteborg screening trial stopped inviting men after the age 
of ~70 years. Considering that 26 out of 112 deaths in the screening group 
occurred in men diagnosed post screening, it seems logical to assume that 
this was too early for men in apparent good health. We have previously 
published data showing that the protective effect of screening disappeared 
after 9–10 years (257). 
When screening does not apply to all men. Almost a quarter (n = 2,310) of all 
men who were invited to the programme never participated (non-attenders). 
Notably, these men had both a higher all-cause mortality (RR 2.34) and 
higher PC-specific mortality (RR 3.23) than attenders. They also had higher 
mortality compared with men in the control arm (RR 1.63), in which 
opportunistic screening increased over the last decade (258). However, there 
is insufficient knowledge concerning the characteristics of non-attenders in 
PC screening. Studies of cervical cancer screening have suggested that non-
attenders have less contact with their general practitioner and that they were 
more often live alone (259), and also that people from ethnic minority 
backgrounds are more likely to be unaware of screening (260). Although the 
features of non-attending men in PSA screening have not been identified, this 
is a group that might require extra attention if a PC screening programme is 
introduced in Sweden. We found that more than 40% of all deaths in men 
randomized to screening occurred in non-attenders.  
This investigation reveals that the men at high risk of PC death were those 
who were invited, but did not participate in the program, those who started 
screening after age 60, and those who had a long life-expectancy and 
terminated screening too early. To improve a future screening programme 
these findings must be regarded. 
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All men in the Göteborg screening trial who terminated the programme at the 
upper age limit of ~70 years had received a letter notifying them that no 
further PSA tests were recommended, and that they had a low risk of future 
PC. To the best of our knowledge, this was based on the information 
available at the time the screening trial was initiated (in 1995). As described 
in Paper IV, we found that being free of PC at time of the final screening is 
no guarantee that GS ≥7 disease will not occur, and as many as 21 men in 
that study-population later died of PC. So, the question is, can we safely 
refrain from prolonged PSA screening in men older than 70 years? From the 
findings in our study, this seems questionable.  
In Sweden today, the estimated age at PC death is 82 years. The average 70-
year-old man has a life-expectancy of ~15 years, (Figure 21), and men in 
good health live even longer. Guidelines (116, 261) recommend against 
screening in elderly men due to the high rate of overdetection. However, 
studies have found that outcomes of surgery for localized PC are similar for 
older and younger men (262), and there is even some evidence that active 
treatment has a survival advantage in the age group 65–80 years (263). 
 
Figure 21. Life expectancy of men in Sweden. Data from the National Board of Health and 
Welfare (www.socialstyrelsen.se). 
Data from the Nordic Cancer Registries (32) shows that PC-specific mortality 
is declining in men aged 75–84 years but increasing in men older than 85 
years. Considering that the ageing population is getting healthier due to 
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improved diagnostics and better treatments (also for many diseases other than 
PC), it is plausible that PC mortality in the oldest men will continue to rise in 
the future. 
Even if it is unlikely that all PC deaths can be prevented, it is reasonable to 
suggest that some of the PC deaths in our study could have been avoided with 
a different stop age. How long such a continued follow-up should be is 
unknown, but our data show that median age for diagnosis was 74 years. 
Advocating that healthy 70-year old men with PSA levels of >1.5 ng/mL 
should be screened until the age of 74–75 might be a vigorous approach (in 
terms of overdetection), although this could also increase the chance of 
detecting aggressive cancers in those who would have a survival benefit from 
diagnosis. 
 
Figure 22. PC specific mortality in elderly Swedish men during the last six decades (32). Men 
older than 85 years have had no decline despite PSA testing becoming more accessible 
(opportunistic testing) in the late 1990s. 
The findings of this investigation further indicate that men with an end-of-
trial biopsy and a PSA level in the range 3–10 ng/mL were at lower risk of 
GS ≥ 7 PC than men with PSA levels of 2–3 ng/mL. Men with higher PSA 
levels most likely had BPH (or an anteriorly located PC) since these subjects 
had been thoroughly screened and biopsied before leaving the screening trial. 
Such men are usually monitored (often by their general practitioner) after 
terminating the screening trial. Men with PSA levels in the range 2–3 ng/ml, 
on the other hand, do not receive any follow-up, which in this cohort (with 
still limited follow-up) resulted in 6 PC deaths.  
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6 FUTURE PERSPECTIVES 
The discussion in this thesis has considered the outcomes of PC screening 
and risk prediction. It is clear that PSA screening reduces PC-specific 
mortality and that PSA is a strong predictor of future PC diagnosis. However, 
overdiagnosis is a major problem that needs to be tackled by improving 
screening strategies, such as better risk stratification and individualized 
protocols. A “one-size-fits-all” solution is not optimal. For example, a  
53-year-old man with a PSA of 2.8 ng/mL is at much higher risk of an 
aggressive PC than a man who is of the same age but has a PSA level of 1.1 
ng/mL. The 53-year-old man with a PSA of 2.8 ng/mL is among the top 10% 
at that age, and it has been shown that such a PSA value corresponds to a  
10-fold higher risk of later aggressive PC (203). Despite that knowledge, 
most urologists (and guidelines) would give the same advice to both these 
men: DRE and a new PSA in 2–4 years. 
Screening is no longer a question of “yes or no”. Many men are already 
having PSA tests on a regular basis, albeit on their own initiative and in a 
suboptimal age rang (i.e., 75–85 years). The question is whether testing 
should be “organized or unorganized”, which is presently a matter of political 
concern. From the perspective of quality assurance, it would be possible to 
improve outcome and collect information by systematizing PSA testing in 
voluntary nationwide programmes. Some counties in Sweden are now 
investigating whether this can actually be achieved, and, if so, how it can be 
done. A project of this type can address specific research objectives, 
including several essential questions that need to be considered and further 
analysed: 
• When should screening start and stop?  
• Should screening intervals be fixed or based on risk-
stratification? 
• What PSA cut-off is the optimal, and should the cut-
off be fixed or based on values related to age? 
• Should complementary biomarkers be applied, and, if 
so, what test should be used? 
• Should complementary imaging (MRI) be used, if so, 
should it be done before or after other additional tests?  
• How should men with benign biopsies be monitored? 
• How should invitations and information regarding 
screening be designed, and is there a better way to 
reach non-attenders? 
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Some of these issues have been thoroughly penetrated by other researchers. 
Colleagues at the Memorial Sloan Kettering Cancer Center in New York, 
have addressed some of these questions and have developed 
recommendations on PC screening (184), that are worth considering. Our 
view is that men in Sweden should be offered information on “organized PC 
testing”, which can involve more than just the PSA test. They should 
therefore be given the option to participate in organized programmes, where 
further assessments of PSA, additional biomarkers, and imaging techniques 
can be made. Such programmes would have to be coordinated within and 
between the different counties. Some Swedish hospitals have recently begun 
performing sequential diagnostic procedures (264), and it will be very 
interesting to see what the future holds in this context. 
Future considerations  
A nationwide population-based screening programme for PC will increase the 
number of men being diagnosed and treated, which in turn will require well-
established organizations and qualified personnel. It is therefore of the 
outermost importance to have a meticulous plan for how a screening 
programme should be arranged and financed. It is essential that hospitals are 
not burdened with an impossible mission in which the expectations are high 
and patients with other diseases are caught in the middle. It is also of ethical 
concern to ensure that men who are invited to and diagnosed within a 
screening programme are offered consultations and treatments within the 
time periods stipulated in standardized care processes. Despite huge efforts in 
recent years, the waiting times for cancer patients in Sweden are still much 
too long, 117–280 days for PC (265).  
In summary, the main obstacle in PC screening is the large risk of 
overdiagnosis, related to PSA testing and systematic biopsies. To decrease 
the harm-benefit ratio, we need to focus on developing the screening 
algorithm of tomorrow. Several promising strategies are currently being 
evaluated: 
• Better and more selective biomarkers such as the 4Kscore, 
the STHLM3 model and the PHI test. 
• Use of imaging to optimize the biopsy procedure (in selected 
men). 
• Tissue markers, to select men who have “high-risk features” 
and hence not suitable for surveillance. 
• Optimization of the age span for testing, to enable a more 
individualized approach. 
Prostate Cancer Screening: Outcomes and Risk Prediction   
 
 93 
Two large research projects are ongoing in Sweden: the STHLM3 MRI 
project (266) and the Göteborg-2 trial. 
The Göteborg-2 trial (G2) 
The G2 trial was initiated in 2015, based on the findings from a pilot study 
(236). The aim of this trial is to investigate whether mp-MRI can improve PC 
screening creating a better balance between harms and benefits, primarily by 
reducing the rate of overdiagnosis. In this RCT, 60,000 men in the Western 
Region (Västra Götalands Regionen) are randomized in a 2:1 ratio to a 
screening- or a control group. The 20,000 men in the screening group are 
offered a PSA test and are subsequently randomized to one of the study arms 
(designated I–III): 
I. The reference group, whit the PSA cut-off level set at 3 
ng/mL. Men with values above this threshold are invited to 
undergo mpMRI followed by a 10-core TRUS guided 
biopsy. For those who have a suspicious lesion on MRI, four 
additional cores, targeted to that area are to be taken. 
II. Arm II is the first experimental arm, whit the PSA cut-off 
level set at 3 ng/mL. Men with elevated PSA are invited to 
mpMRI, but only have targeted (no systematic) biopsies, 
thus men with no lesion on MRI will not be biopsied. 
III. Arm III is the other experimental arm, whit the PSA cut-off 
level set at 1.8 ng/mL. Otherwise uses the same schema as in 
the experimental arm II. 
The pilot study was published in 2016 and showed promising results with the 
approach in arm III (236). The endpoint in the G2 trial is the rate of  
GS ≥ 7 cancers detected in various arms. Results from the first round are 
expected to be published in 2020. 
Before introduction of a national screening program for PC, further 
evaluation of men’s experience from screening would be valuable. We need 
to assess how men interpret recommendations given in a screening setting. 
Information and individualized decision making are central. It is therefore 
more appropriate to strive to reach non-informed men rather than to reach 
non-attenders, since not attending may be a rational choice after information. 
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7 CONCLUSIONS 
Voiding symptoms are generally not a sign of PC in men with elevated PSA.  
The initial PSA level can be used to predict men’s long-term risk of PC. 
The free-to-total PSA ratio has no additive value to PSA and should not be 
used as a reflex test in men with a PSA level below 3 ng/mL. 
Men die despite screening, which shows that the current screening algorithm 
has pitfalls. 
Screening saves lives by reducing PC-specific mortality by ~30%. 
The outcomes of PC screening can be improved by starting PSA screening 
before the age of 60 years, improving attendance rates, and offering men with 
long life expectancy additional testing after the age of 70. 
Men who participate in a screening programme and are free of PC at the time 
they terminate screening due to the stipulated stop age, are still at risk of 
high-grade disease and PC death. 
PC deaths can be prevented by offering healthy men additional testing after 
the age of 70 years. 
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SVENSK SAMMANFATTNING 
Den vanligaste cancerformen i Sverige är prostatacancer (PC). Sjukdomen 
drabbar främst äldre män. Mer än 70 % av de ca 10 500 män, som årligen 
diagnosticeras är över 65 år. Denna cancerform är vanligen långsamt växande 
och har en lång och symptomfri fas, då sjukdomen (om den upptäcks) kan 
behandlas och botas. Genom tidig upptäckt kan man undvika spridning till 
andra delar av kroppen. Män som får symptom av sin tumör har ofta en långt 
gången och icke botbar sjukdom. Sedan mitten på 90-talet kan män, genom 
ett enkelt blodprov, testa sig med så kallat prostataspecifikt antigen (PSA). 
PSA-provtagning syftar till att upptäcka PC. Den största nackdelen med 
PSA-testning är att många av de män som diagnosticeras aldrig skulle ha 
utvecklat en farlig PC. Detta kan medföra oro, onödiga behandlingar och 
behandlingsrelaterade biverkningar, som till exempel nedsatt sexualfunktion, 
urinläckage och tarmbesvär.  
Under våren 2018 bedömde Socialstyrelsen att fördelarna med allmän  
PSA-provtagning (screening) inte uppväger nackdelarna. Denna 
rekommendation startade en omfattande debatt i Sverige, och många män 
väljer ändå att testa sig. Dessvärre leder denna typ av okontrollerad PSA-
provtagning till att många män testar sig i fel ålder, ofta med bristande 
information och fel uppföljning. På vilket sätt ett framtida screeningprogram 
bör utformas är inte fastställt, och det pågår även en världsomspännande 
diskussion beträffande huruvida PSA-screening verkligen minskar 
dödligheten i PC.  
Denna avhandling fokuserar på utfall och prediktion inom en screeningstudie, 
med syfte att öka förståelsen för PSA-screening. Delarbetena i avhandlingen 
härrör från en stor randomiserad, populationsbaserad screeningstudie, som 
startades 1995 i Göteborg, med 10 000 män i respektive grupp (en screening- 
respektive en kontrollgrupp). De screenade männen har erbjudits PSA-prov 
vartannat år och prostatabiopsi (cellprov) om värdet varit > 3.0 ng/ml. 
Männen som lottades till kontrollgruppen har inte fått någon inbjudan till 
PSA-provtagning, men de har haft tillgång till PSA-testning utanför studien 
(på eget initiativ). Under våren 2014 avslutades den 10:e och sista 
screeningomgången. Göteborgsstudien är unik på många sätt och har idag 
den längsta uppföljningstiden av alla screeningstudier i världen (22 år).  
I arbete I har vi undersökt om män med förhöjt PSA och vattenkastnings-
besvär hade större risk för PC än män utan symptom. I studien användes ett 
frågeformulär avseende vattenkastningssvårigheter. Männen genomgick 
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ultraljud och cellprovtagning i samband med läkarbesöket. Totalt 
analyserades svar från 2 353 män som genomgick undersökning i samband 
med sin första screeningomgång. Logistisk regression med variablerna: ålder, 
kvot PSA, prostatavolym och symptom användes med utfallsmåttet PC. Vi 
fann att ålder (odds ratio (OR) = 1.1), prostatavolym (OR 0.96), kvot PSA 
(OR 0.97), PSA (OR = 1.09) och vattenkastningssymptom (OR = 0.78) var 
statistiskt signifikant relaterade till risken för PC hos män med PSA över  
3.0 ng/ml. Ett OR på 0.78 talar för att män med symptom har lägre 
sannolikhet för PC än män utan symptom. Från studien kan man dra 
slutsatsen att vattenkastningsbesvär vanligen inte är tecken på PC hos män 
med förhöjt PSA. Män med dessa besvär utgör inte en högriskgrupp och bör 
således utvärderas på samma sätt som övriga män med PSA över 3.0 ng/ml. 
I arbete II har vi utvärderat hur den initiala PSA-nivån påverkar senare 
cancerutfall och död i PC. Analysen utgick från de 5 174 män som hade PSA 
< 3 ng/ml vid första screeningomgången. För att utvärdera det prediktiva 
värdet (möjligheten att förutsäga PC) av ålder, PSA och kvot-PSA för 
framtida insjuknande i PC användes Harrell’s c-index baserat på Cox 
regression. Vi fann att ålder och PSA, men ej kvot-PSA var associerat med 
risken för framtida PC. Män med PSA < 1.0 ng/mL hade efter 19 års 
uppföljning en kumulativ PC risk på 8 % medan män med PSA i intervallet  
2 till 2.99 ng/ml hade 40 % risk för PC. Risken för död i PC ökade från 0.3 % 
till 1.5 % beroende på männens ursprungliga PSA-nivå. Totalt dog 28 män av 
sin cancer (trots att de deltog och hade ”normala PSA-värden” vid 
screeningens början). Slutsatsen blev att det initiala PSA-värdet var starkt 
kopplat till framtida utfall. Dessvärre tillförde inte ett tilläggsprov med så 
kallat kvot-PSA (kvoten mellan fritt och totalt PSA) något till PSA och är 
således inget användbart tilläggstest vid PSA under 3.0 ng/ml. 
I arbete III analyserades effekten av organiserad PSA-screening med lång 
uppföljning (22 år). Studien analyserade även vilka subgrupper av män som 
trots screening hade en ökad risk för död i PC. Vi jämförde screening- och 
kontrollgruppen med en fiktiv jämförelsegrupp, där insjuknande och död i PC 
baserade sig på data från 1990–1994, då PSA-provtagning i Sverige var 
mycket sällsynt. På så sätt kunde vi uppskatta hur dödligheten skulle ha sett 
ut om ingen PSA-provtagning fanns att tillgå. Männen i kontrollgruppen har 
inte inbjudits till PSA-screening i studien, men många har testat sig på eget 
initiativ (utanför screeningstudien). Resultaten visade på att organiserad PSA-
screening minskar PC dödligheten med ca 30 % och med nästan 50 % om 
man jämför med den fiktiva gruppen (baserat på att ingen PSA testning 
skett). För att förhindra en man från att dö av PC behövde vi bjuda in 217 
män och diagnosticera 9. De män som hade högst risk för att dö av PC var de 
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män där screening initierades efter 60 års ålder, de som bjöds in men inte 
deltog samt de män med förmodad lång överlevnad, där screeningen 
avslutades för tidigt. För att ytterligare minska dödligheten behöver åtgärder 
fokuseras på att optimera start- och stoppålder samt minska antalet icke-
deltagare. 
Studien som rapporteras i arbete IV undersökte om en övre åldersgräns på  
70 år (för ett screeningprogram) är tillräckligt hög eller om vissa grupper 
skulle vara betjänta av screening även i högre åldrar. Analysen inkluderar 
4 464 män som deltog vid sitt sista screeningtillfälle. De var då mellan 67–71 
år och hade ej diagnosticerats med PC under screeningperioden. Männen 
följdes upp i ca 9 år efter att de avslutad screening. Genom så kallad Cox 
regressionsanalys och Harell’s c-index kunde olika faktorer (prediktiva 
variabler) med eventuell inverkan på framtida utfall utvärderas. Totalt 
hittades 186 PC-fall (varav 65 % var höggradiga) och 21 män dog av PC 
under uppföljningstiden. Män som avslutade studien med ett godartat 
cellprov och PSA 3–10 ng/ml hade en lägre risk för aggressiv PC, jämfört 
med de män som ej lämnat cellprov och hade PSA 2–3 ng/ml. PSA-nivån vid 
sista screeningtillfället var annars en viktig faktor och majoriteten av männen 
som dog hade ett PSA > 1.5 ng/ml vid sista provtagning i screeningstudien. 
Genom att fortsätta screena ca 40 % av männen (de med PSA > 1.5 ng/ml) 
även efter 70 års ålder, skulle vi kunna hitta 80 % av de som utvecklar farlig 
PC och dör av sin sjukdom.  
Slutsatser  
Män med ett förhöjt PSA och vattenkastningsbesvär hade en lägre risk för PC 
jämfört med män utan symptom. 
PSA-värdet vid första screening tillfället har stor betydelse för framtida 
cancerutfall, då PSA-nivån ligger under åtgärdsgränsen då mannen börjar 
screena sig i studien. Att en del män dör av PC trots att de deltar aktivt i 
programmet, talar för brister med nuvarande screeningupplägg. Kvot-PSA är 
inget användbart tilläggstest i PSA-nivåer under 3.0 ng/ml. 
Organiserad PSA-screening minskar risken att dö av PC (med ca 30 %) 
jämfört med de män som inte bjuds in. De som har störst risk för PC död är: 
män som börjar screena sig för sent (efter 60 års ålder), de som bjuds in men 
inte deltar och de män som har lång förväntad överlevnad och slutar PSA-
screening för tidigt (vid ca 70 års ålder). 
Selekterade män bör erbjudas screening även efter 70 års ålder. 
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